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Although the incidence of new cases of asthma has decreased in recent years, the prevalence of 
asthma morbidity continues to be a significant clinical and public health issue.   The measures of 
morbidity include the need for urgent medical care and high-dose asthma medications due to 
uncontrolled asthma symptoms.   However, the risk factors for uncontrolled asthma symptoms 
are poorly defined, especially for the adult asthmatic.  Much interest in the host-environment 
interaction has evolved in response to the greater morbidity observed in adult asthmatics.  Thus, 
the need to identify risk factors is greater than ever.  An underlying problem is that surveillance 
for asthma does not exist at the local or state level. Here we address the concept of 
environmental health surveillance by demonstrating the utility of local asthma hospitalization 
data to estimate the burden of asthma morbidity in hopes of identifying environmental risk 
factors.  We examine this burden within 2 geographic settings: 1. a selected urban-rural setting in 
Pennsylvania and 2. within the 89 zip codes in Allegheny County, Pennsylvania.  We also 
demonstrate that such hospitalization records are a rich source for data needed to generate 
hypotheses with respect to the prevalence of environmental risk factors and chronic disease 
morbidity. Lastly, we demonstrate the use of a non-invasive biomarker (i.e. antibodies specific 
for atypical respiratory pathogens) to assess the risk of exposure to a biological environmental 
agent to adult asthma morbidity.  Given the poor understanding of risk factors for adult asthma 
prevalence and morbidity, this research is both relevant and important in addressing 
environmental public health disparities.   
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1. INTRODUCTION 
 
 
1.1. Overview of asthma 
 
  
Prevalence of disease. Asthma currently affects 7.4 million people over the age of 15 in the 
United States (Arif et al., 2003; Mannino et al., 2002).  Although asthma-specific mortality rates 
for this age group have decreased, the increasing number of hospitalizations and attacks continue 
to be a significant problem (Arif et al., 2003).   The prevalence of asthma morbidity in the US, 
specifically the need for frequent medical care, has increased steadily in the last decade (E. S. 
Ford et al., 2003).  A similar increase in prevalence of asthma has also been reported in Western 
Europe (ENFUMOSA, 2003).  These phenomena are not restricted to the US or “developed 
westernized” countries.  The increasing incidence and prevalence is also reported in developing 
countries like Chile and China (Chan-Yeung et al., 2002; Corvalan et al., 2005; Rona et al., 
2005).  Thus, asthma should be considered a multi-factorial disorder with varying etiological and 
heritable factors (Lemanske & Busse, 2003).  
 
       Local surveillance for asthma incidence and prevalence does not currently exist.  This is 
most likely due to the fact that asthma is not an infectious disease and has a low mortality rate.  
However, the prevalence of asthma morbidity is monitored by the Centers for Disease Control 
(CDC).  The CDC uses health care utilization information to estimate the prevalence of asthma 
morbidity (C. D. C. National Center for Environmental Health, 2003).  The information is 
collected from two of their programs: the National Hospitalization Discharge Survey (NHDS) 
and the Behavioral Risk Factor Surveillance Survey (BRFSS).  The data and subsequent analysis 
resulting from these two programs are periodically published in the CDC’s Morbidity and 
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Mortality Weekly Report (MMWR).   The latest asthma-specific MMWR in 2002 stated that 40 
million people responding to the BRFSS reported being diagnosed with asthma by a physician 
(Mannino et al., 2002; C. D. C. National Center for Environmental Health, 2003). In addition, 
the latest NHDS in 2004 reported that 57,000 asthma hospitalizations occurred during that year 
(National Center for Health Statsitics, 2004).    
 
       Asthma, previously thought to be a childhood disease, has also increased in prevalence 
within the adult population (Brogger et al., 2003).   Adult asthmatics report more frequent use of 
health care for asthma symptoms and often have more diminished lung function than child 
asthmatics (Bel, 2004).  Asthma severity, including a more frequent need for high dose (ie 
corticosteroids) and rescue medications (ie short-acting beta-agonists), is also more common in 
adults than in children (Lemanske & Busse, 2003).  Finally, the gender distribution in child 
asthma vs adult asthma is different.  For childhood asthma, the male to female ratio is 2:1 
whereas the same ratio is adult asthmatics is 1:2 (Fuhlbrigge et al., 2002).   
 
Patho-physiology of asthma.  Asthma is a chronic inflammatory disease that affects both adults 
and children (Lemanske & Busse, 2003).  Although there is not a cure for asthma, many children 
have been reported to “outgrow” their asthma symptoms.  However, studies investigating the rate 
of remission during adulthood are few.  Asthma can be managed quite effectively with the use of 
corticosteroids, the cornerstone drug for asthma (Peters, 2004).  Recently, therapy has been 
expanded to include the use of additional controller medications such as long acting beta 
agonists, leukotriene modifiers, and anti IgE medication (Ilowite et al., 2004).   
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       The heterogenous nature of asthma is the presents a major obstacle in the proper diagnosis 
and management of this disease (NHLBI, 1997).   The lack of uniformity in diagnosis and 
disease severity classification has been a challenge with respect to asthma management 
(Bacharier et al., 2004; Baker et al., 2003).  Within the public health context, the primary interest 
is the identification of risk factors that influence disease severity and the recognition of these risk 
factors by clinicians and patients alike (Arruda et al., 2005).   Previously thought to be a 
childhood disease, adult-onset asthma has emerged in the past decade as a major public health 
issue (W. Busse et al., 1995).   
 
       The adult-onset asthmatic tends to have greater measures of morbidity (i.e. rapidly declining 
lung function) than the asthmatic who was diagnosed as a child (Bel, 2004).    Previous studies 
have also cited that the diminished lung capacity in the adult-onset asthmatic is not reflective of 
disease duration (Jenkins et al., 2003). Thus, it is a common theme amongst researchers that 
adult-onset asthma may be a distinct disorder from childhood-onset asthma.   
 
       At the cellular level, adult asthma can also be distinguished from childhood asthma.   
Whereas childhood asthmatics have a greater involvement of cellular components indicative of 
atopy and allergy (i.e. eosinophils and IgE), the adult asthmatic tends to be non-atopic and has 
greater measures of severity including the involvement of neutrophils (ENFUMOSA, 2003).    
Adult asthmatics have also been reported to produce a larger amount of enzymes known as 
matrix metalloproteinases (i.e. MMP-9) that are involved in the remodeling process within the 
bronchial epithelium (Cundall et al., 2003).  The source of MMP-9 in these studies has been 
neutrophils.  Finally, although corticosteroids are very effective in reducing inflammation caused 
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by eosinophils (Bloom et al., 2004), they are much less effective at reducing inflammation 
caused by neutrophils (Cundall et al., 2003).   
 
The economic burden of asthma. It is estimated that approximately 10% of adult asthmatics can 
be classified as severe (W. W. Busse et al., 2000).  However, this sub-group of asthmatics shares 
a disproportionate burden of direct medical costs related to asthma (Godard et al., 2002). Total 
direct medical expenditures for asthma care in the US are estimated to be in excess of $11.3 
billion, not including indirect costs such as lost work days. This figure, estimated to be 60% of 
the $14 billion spent annually for medical care, is primarily attributed to pharmacological agents 
(Apter et al., 2003). 
      
1.2. Health disparities and asthma 
 
Population-based disparities.  In 2000, the US Public Health Service’s goals for the decade were 
outlined in the document Healthy People 2010 (HP 2010) (U.S. Department of Health and 
Human Services, 2000).    Aimed at eliminating health disparities, HP2010, identified disease-
based goals and objectives where disparities have been clearly documented and where in many 
cases were preventable.  One of the goals addressed asthma incidence and prevalence.  A key 
question was why asthma mortality continued to decrease but measures asthma morbidity 
continued to increase.   Published studies identify the way health care is delivered in the US as 
the culprit (Adams et al., 2003).   The argument is that adequate preventive health care is often 
an expense that is not covered by private health insurance thus those with less disposable income 
are likely to seek medical attention unless the need is dire.   But disparities are seen in countries 
outside the US that are clearly influenced by socioeconomic status (Basagana et al., 2004).  
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Interestingly, each measure of SES is different so regardless of how you measure social class, the 
lower stratum often shares a disproportionate burden of asthma morbidity (Cesaroni et al., 2003; 
Y. Chen et al., 2004b).  One tool being used to address this disparity is through patient education 
which involves increasing the patient’s perception of the risk conferred by poor control of their 
asthma (i.e. need to adhere to medication protocols) and reduction of exposure to environmental 
risk factors (i.e environmental tobacco smoke) (Castro et al., 2003).   
 
       With respect to asthma, the issue of race/ ethnicity and disparities in health outcomes has 
gained widespread attention (Burchard et al., 2004).   A contributing factor to the race/ ethnic-
specific health disparities is that racial and ethnic minorities are overrepresented in the 
population that is currently living below the federal poverty guidelines (Boudreaux et al., 2003).   
Related to the availability or lack of disposable income are housing choices.  Often affordable 
housing is located in neighborhoods where continuous environmental exacerbations, especially 
for those with respiratory disease, exist.   Thus we realize that a large contribution to higher 
health disparities in racial and ethnic subpopulations may be income-related.   
 
       With the advancements being made in pharmacogenomics, population-specific risk of 
asthma exacerbations due to certain asthma drugs have been identified (J. G. Ford et al., 2002).  
New research regarding race-specific polymorphisms may help to explain why certain subgroups 
within the asthmatics population have a higher frequency of poor response to asthma (R. G. Barr 
et al., 2001; Federico et al., 2005).  However controversial, the use of phamcogenomics and 
toxicogenomics to investigate race- and ethnic-specific health disparities is regarded as 
promising.   
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Geographic-based disparities (urban vs rural) Recent studies regarding the variable distribution 
of asthma incidence and prevalence have been conducted in Europe  (Eder & von Mutius, 2004).   
A hypothesis for this distribution known as the “hygiene hypothesis” states that early exposures 
to rural elements in the environment (i.e. livestock and endotoxin) confer a protective risk for 
developing allergy and asthma as child (Adler et al., 2005).  However, these same exposures (i.e. 
endotoxin) are well-published risk factors  for exacerbation of asthma symptoms in adults 
(Merchant et al., 2005). Thus, an increased emphasis has been placed on the timing of exposures 
(de Marco et al., 2004).   In the US, studies investigating the prevalence of asthma and asthma 
morbidity within the context of the urban-rural environment have been few.  This is likely due to 
the fact that the definition of rural in the US is varied.  However, many studies have been 
conducted assessing the relationship of urban characteristics and the incidence, prevalence, and 
morbidity of asthma (Crain et al., 2002; Kim et al., 2004b; Kunzli et al., 2003; U.S. Department 
of Health and Human Services, 2000).  These characteristics of urban life include such as traffic 
density, population density, and poor housing.  However, there have been very few published 
reports comparing these characteristics within the urban-rural context and assessing their effect 
on asthma.   
 
1.3 Cellular events that contribute to asthma morbidity 
   
Characteristic features of asthma include reversible airflow obstruction and hyperresponsiveness 
in the upper and lower airways (W. W. Busse et al., 2003). Asthma research has focused on 
mechanisms of airway inflammation, regulation of these processes, and how these events result 
in altered lung function due to tissue remodeling.  
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Inflammation.  Airway hyperresponsiveness to a variety of environmental stimuli is one of the 
characteristic features of asthma (NHLBI, 1997).   These stimuli include may include those that 
are chemical (i.e. irritants), physical (i.e.cold air), or biological (i.e. respiratory pathogens) in 
nature.   In all cases, the result is an inflammatory response that involves an increased production 
of granulocytes, particularly eosinophils once considered to be a bystander cell in during the 
immune response.   Studies have shown  that eosinophils exacerbate and prolong inflammatory 
responses in asthma by the production of immune regulatory cytokines, chemokines, and growth 
factors (Adamko et al., 2002).  These factors further aggravate inflammation during an asthma 
attack by attracting more cells to the site of inflammation and activating these on their arrival.   
In asthma, eosinophils are thought to self-propagate and prolong their own survival through the 
production of cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF).    
 
The Th1 vs Th2 paradigm in asthma. In 1994, 2 subsets of T helper lymphocytes were identified 
and come to be known Th1 and Th2 cells (Mosmann et al., 1986).  Studies since have shown that 
that activated Th2 lymphocytes and the production of certain cytokines such as interleukin (IL)-
4, IL-13, and IL-5 are responsible for eosinophil activation and IgE production (Chinen & 
Shearer, 2003).  For asthmatics, this set of events results in the underlying inflammation 
responsible for asthma symptoms (Lemanske, 2000).  Although the Th1 and Th2 subsets develop 
from the same precursor cells known as naïve CD4+ T lymphocytes their differentiation is 
determined by environmental stimuli present early during immune responses.  
 
       Th2 differentiation occurs in response to environmental allergens and helminths via 
activated antigen-presenting cells under the influence of IL-4 (Ngoc et al., 2005).  Activated Th2 
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lymphocytes produce IL- 4, IL-13, and IL-5, which are responsible for IgE production by B 
cells, eosinophil activation and recruitment, and mucus production (Liu et al., 2004).   In 
contrast, Th1 cells differentiate from naïve CD4+ cells in response to microbial activation of 
antigen-presenting cells under the influence of IL-12. Differentiated Th1 cells secrete interferon-
gamma (IFN- γ) which is important in the intracellular destruction of phagocytosed microbes. 
Furthermore, IFN- γ  produced by Th1 cells and IL-4 produced by Th2 counter-regulate each 
other.   Early asthma studies focused on a the T-cell repertoire, specifically the Th1/ Th2 
“imbalance”,  in hopes of explaining the pathophysiology of asthma (Umetsu et al., 2003).  
However, recent studies have identified the other players such as T-regulatory cells and natural 
killer (NK) T-cells  as having a more prominent role in asthma.    Thus, the explanation of 
asthma patho-physiology using the Th1/ Th2 paradigm may have been an oversimplification of a 
complex disease.    
 
Remodeling.  Airway remodeling is a term that is indicative of changes in the composition, 
quantity and organization of the cellular and molecular components of the airway wall (S. T. 
Holgate et al., 2004).   The epithelial–mesenchymal trophic unit is a concept that describes how 
the integrity of the airway wall depends upon the maintenance of signals between the epithelium 
and the underlying mesenchyme.  The mesenchyme is a basement membrane surrounded by 
layers of fibroblasts, ECM (extracellular matrix) and smooth muscle cells that is  interspersed by 
vessels, neural elements and an immune network. It is the disruption of this trophic state leads to 
airway remodeling.  In asthma, the disruption is caused by airway hyper-responsiveness (AHR) 
and inflammation.   
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       An increase in the thickness of the layer immediately beneath the basement membrane, 
known as fibrosis, has been an observed in asthma and increases proportionately with disease 
severity (Matsumoto et al., 2005).  Multiple studies have also documented the thickening of the 
airway wall in asthma. Although some of this thickening may be temporary due to inflammation, 
most are likely permanent.  The permanent changes in basement membrane thickness involve 
matrix deposition and increased muscle mass and increases with both disease severity and 
duration of asthma (Bai & Knight, 2005; Cundall et al., 2003).   
 
1.4 Heritability, genetics and asthma 
 
Familial. Parental atopy has been identified as a risk factor for childhood asthma (Jaakkola et al., 
2005).  Jaakkola, et al reported that the likelihood of children of developing asthma was greater 
if their parents were atopic (IRR = 1.52, CI =1.08-2.13).  Further investigation into the influence 
of parental asthma history on the risk of childhood asthma revealed that a higher risk is conferred 
by the father’s asthma status than the mother’s (Alford et al., 2004).  Asthma status in the 
fathers, whether it was childhood-only, adulthood-only, or persistent, was associated with current 
asthma in the children. These investigators also reported a significant relationship between 
allergy in the father and atopy in the study children.    An additional study found that children 
whose parents were atopic were more likely to have positive dust mite skin test (Cole Johnson et 
al., 2004).    
 
Candidate asthma genes and pharmaco-genomics.  ADAM 33, the first gene identified as a 
candidate for asthma, now has a postulated role in myogenesis, airway modeling, and signaling 
via protein shedding (Blakey et al., 2005).  Recently, a variant in ADAM33 was identified 
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(Jongepier et al., 2004).  The authors concluded that this variant may not only important in the 
development of asthma but also in disease progression and enhanced airway remodeling. With 
the progress being made in the field of genomics, we are likely find that environmental factors 
do influence the expression of genes and the ultimate clinical phenotype of asthma and atopy 
(Blumenthal, 2005).  Additional studies have addressed polymorphisms in cellular receptors and 
surface markers required for the inflammation seen during asthma.  Alterations in the genes 
encoding for the interleukin (IL)-8 receptor (Stemmler et al., 2005), IL-4 (Basehore et al., 2004), 
and the major histocompatibility coplex (MHC) (Aron et al., 1999) all have potential 
implications with respect to the inflammatory process seen in asthmatics.   With respect to 
pharmacotherapy, polymorphisms in the genes encoding for the B-adrenergic receptor and the 
glucocorticoid receptor (Hawkins et al., 2004) may have implications with respect to the drug 
therapy and the control of asthma symptoms.  Finally, understanding why asthmatics have a lack 
of tolerance to common environmental stimuli may be realized with the identification of 
polymorphisms in the genes encoding for toll-like receptors, a key player in the innate immune 
response (Davies, 2001; Lazarus et al., 2004).    
 
Gene-environment interaction. As previously mentioned, polymorphisms in the genes that 
regulate our tolerance for common environmental stimuli have been identified (Aron et al., 
1999).   Deficiency of the antioxidant Glutathione–S–Transferase (GST)  in children and in utero 
exposure to passive environmental tobacco smoke has been associated with  the development of 
asthma (Kabesch et al., 2004).     The lack of antioxidants obtained through diet and 
polymorphisms in the gene encoding for a class of GST  have been associated with asthma and 
wheeze in children who live in areas with high levels of ozone (Romieu et al., 2004).  
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Polymorphisms in the gene that encodes for the enzymes that modulate the production of the 
cysteinyl-leukotrienes (cys-LTs), another class of proinflammatory mediators in asthma (Kedda 
et al., 2004).  This could explain why certain asthmatics are not able to tolerate aspirin as cys-
LTs are produced as a by-product after aspirin ingestion.  With the identification of toll-like 
receptors and their respective polymorphisms, the differential response of the host to pathogens 
incurred naturally and during infections is better understood (D. N. Cook et al., 2004; Leung et 
al., 2005).    
 
1.5. Phenotypes of asthma 
 
In the literature, phenotypes of asthma are often described by the clinical manifestations, 
suspected origin, or age of onset.  The following are brief descriptions of the phenotypes of 
asthma within these contexts.            
 
Clinically-based. The term severe asthma most often describes a pathology where persistent 
eosinophilic inflammation exists despite the use of high dose corticosteroids (S. Wenzel, 2003).  
This the term “steroid” resistant has also been used to describe this phenotype (W. W. Busse et 
al., 2000).  
 
Etiology-based.  Aspirin-sensitive asthma has been used to describe the phenotype in which 
asthmatic individuals exhibit severe asthma symptoms upon ingestion of aspirin/ non-steroid 
anti-inflammatory drugs (Morwood et al., 2005).  This phenotype is observed more often in 
severe asthmatics.  Occupational asthma and wheeze has been used to describe airway hyper-
responsiveness due to an “asthmogen” exposure within the occupational setting (Bang et al., 
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2005; Hoppin et al., 2004).  Additional phenotypes such as exercise-induced asthma (Abu-Hasan 
et al., 2005) and cold weather-induced asthma (Storms, 2003) have been reported but their 
prevalence in the general population is not known.   
     
Adult vs Childhood. In children, three asthma phenotypes are now well defined: transient infant 
wheezing, nonatopic wheezing of the toddler, and IgE-mediated wheezing/asthma (Bel, 2004).  
In adults, asthma persisting from childhood into adulthood should be distinguished from asthma 
starting in adulthood.   The risk factors for childhood asthma include atopy (Arshad et al., 2005), 
respiratory viruses (Gern et al., 2005), and exposure to cigarette smoke (Arruda et al., 2005; 
Cantani & Micera, 2005).  However, much less is known about the risk factors for adult-onset 
asthma.   
 
1.6. Risk factors for adult asthma morbidity 
          
 
Female gender. The prevalence of female within the adult asthma population has been well 
documented (Arif et al., 2003).  However, the contributing factors to this trend are less known.  
In 2004, Barr et al found that hormone replacement therapy was a risk factor for newly 
diagnosed asthma for women enrolled in the Nurses Health Study (R. Graham Barr, 2004).   
With respect to aspirin-sensitive asthma, polymorphisms within the promoter region of the 
COX2 gene have been identified.  Individuals who are homozygous for this variation have an 
increased production of prostaglandins, are more likely to be female and tend to have the severe 
form of asthma (Szczeklik et al., 2004).   
 
 13
Current age. Current age in addition to nocturnal asthma symptoms and hospitalization have 
been identified as risk factors for asthma morbidity in adults (Ellman et al., 1997).  A recent 
study found that medication and health care utilization (surrogates for disease severity) was 
higher in older adult asthmatic females (Schatz & Camargo, 2003).  
                   
BMI. The role that obesity, as measured by body mass index (BMI), plays in the pathology of 
asthma is unclear. The parallel increase in asthma and obesity raises the question if BMI is a risk 
factor for developing asthma (E. S. Ford, 2005).  In addition, asthmatic adults are more likely to 
be obese when compared to non-asthmatics (E. S. Ford & Mannino, 2005). Recent studies have 
also found that BMI increases with asthma severity (Akerman et al., 2004). The gender-specific 
association of  BMI with asthma has been observed equally in both genders during adulthood 
(Thomsen et al., 2005) but is higher in school-age boys (Gilliland et al., 2003).  The relationship 
between the built environment and obesity and asthma is now a focus of some studies (Brisbon et 
al., 2005).   
                  
Age of onset and length of disease.  Although the length of disease is associated with disease 
severity in child-onset asthmatics, there is no relationship in those who developed asthma as an 
adult (Jenkins et al., 2003).  Length of disease in conjunction with house dust mite allergy and 
aspirin sensitivity were cited as risk factors by Kupczyk, et al (Kupczyk et al., 2004).  Miranda, 
et al found that subjects with early-onset, severe asthma had significantly more allergen and 
more allergic symptoms than subjects with adult-onset asthma (Miranda et al., 2004). This was 
in contrast to adult-onset asthmatics that had lower lung function than early-onset, despite a 
shorter duration of illness.  
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Comorbdities Rhinitis has been shown to be associated with both atopic and non-atopic adult 
asthma (Guerra et al., 2002). Other co-morbidities such as gastroesophageal reflux disease 
(GERD) and chronic sinusitis have been associated with the increased need for high dose 
corticosteroids (Liou et al., 2003).  
                          
Allergy and atopy history. Within the adult asthma population, the atopic and non-atopic 
subgroups have distinguishing characteristics (Nieves et al., 2005; Romanet-Manent et al., 
2002).  Within the non- atopic adult asthmatic group, the majority are female, tend to have adult- 
onset of asthma, have lower lung function, and are older.  Within the atopic group, the majority 
are male, tend to have seasonal allergies symptoms, and are more likely to have developed 
asthma as a child.    
 
 
 
1.7. Environmental triggers of asthma and asthma morbidity 
 
 
         
Chemical.  It has been shown that exposure to cigarette smoke is not only a risk factor for 
childhood asthma, but it also impedes the efficacy of glucocorticoids in adult asthmatics 
(Chaudhuri et al., 2003).  Exposure to high levels of indoor nitrogen dioxide in combination with 
respiratory viral infections is also a risk factor for asthma exacerbations (Chauhan et al., 2003).  
Atopic asthmatics are at an increased risk of exacerbations after exposure to low levels of ozone 
suggesting an increase in allergen sensitivity due to this chemical (L. L. Chen et al., 2004a).  
Another study found an association with the time spent outdoors and respiratory symptoms in 
children who lived in areas with high ozone levels (McConnell et al., 2002).  Other pollutants 
that contribute to the ambient air quality have been associated with asthma exacerbations (Farhat 
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et al., 2005; Kunzli et al., 2003).  In addition to ozone, these pollutants include carbon monoxide, 
particulate matter, nitrogen dioxide, and sulfur dioxide.  Source apportionment of these 
pollutants and the relationship to asthma symptoms has also been investigated (Kim et al., 
2004a).  Kim, et al found that even at low levels of traffic-source pollution, respiratory effects in 
children were observed.  In addition, the respiratory effects decreased as the distance to the roads 
increased.    
 
 
Biological (ie viral, bacterial, fungi).  Individuals with asthma are not at an increased risk for 
rhinovirus (Corne et al., 2002).  However,  virus-induced  (primarily rhinovirus) asthma 
exacerbations is likely be around 80 85% in school-aged children (Contoli et al., 2005).   These 
studies suggest that the asthmatic is more likely to suffer ill-consequences from this synergistic 
relationship.     Interestingly, the relationship of influenza and asthma symptoms is not known 
even though less than 50% of asthmatics report being vaccinated against the flu (E. S. Ford et al., 
2004). The association between bacterial respiratory pathogens and adult asthma severity has 
been published recently (Gencay et al., 2001; Lemanske, 2003; Martin et al., 2001).   However, 
it is not clear if the effect is due to infection or to antigenic response to components of the 
pathogen, such as heat shock proteins (Huittinen et al., 2001; Kinnunen et al., 2001).   Co-
infection with another respiratory bacteria or virus has also been cited as a risk factor for asthma 
symptoms in adults (Lieberman et al., 2003).    
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1.8. Remaining uncertainties with respect to asthma morbidity in adults. 
 
 
It is obvious that much of research regarding risk factors for asthma incidence and asthma 
morbidity has focused on children.  Although it is unlikely that the risk conferred to children by 
tobacco smoke and air pollution is less in adults, the risk conferred by co-morbidities and 
infection is not known.   In addition, without a chronic disease surveillance system at the local 
level, we are not able to address the population distribution of asthma morbidity in either 
children or adults.  Finally, the influence of the protective “rural” environment has not been 
investigated in Pennsylvania.  Of interest if whether this protection is conferred by the presence 
of rural characteristics such as farming and agriculture or by the lack of urban characteristics 
such as traffic and industry.     
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2. SPECIFIC AIMS 
 
 
The overall goal of this research was to address study questions that remain regarding the 
prevalence of, and the risk factors for, adult asthma morbidity.  The specific aims were as 
follows: 
1) To assess if the degree of urbanization (as measured by traffic and population density) 
contributes to adult asthma hospitalizations, within the urban-rural context.   We used 
adult asthma hospitalization data to assess these rates and frequencies for adult asthmatics 
in 6 Pennsylvania counties.   
2) To assess the utility of local asthma hospitalization data as an environmental health 
indicator.  Of interest was the demographic, temporal, and geographic distribution of 
adult asthma hospitalizations for Allegheny County’s 89 zip codes.   
3) To assess the risk conferred to adult severe asthmatics by respiratory infection due to 
atypical respiratory pathogens (i.e. Mycoplamsa pneumonia, and Chlamydia pneumonia).  
For this aim, our study population was a cohort enrolled in the multi-city Severe Asthma 
Research Project.        
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3.1.1 Preface 
 
 
Published investigations regarding the prevalence of asthma morbidity within the urban-rural 
context in the United States are rare.  Here we test the hypothesis that indices of urbanization 
(i.e. traffic, population) are risk factors for adult asthma hospitalizations.   
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3.1.2. Abstract 
 
Asthma research has traditionally focused on children and the elderly, two populations 
considered the most susceptible to complications.  However, the prevalence of asthma in the 
adult population (19-64 years) is gaining recognition as a formidable clinical and public health 
problem.  In addition, few studies have assessed the incidence of adult asthma hospitalizations in 
urban vs. non-urban areas.  Using population size, population density, and traffic-related factors 
to define urban vs. non-urban environments, six Pennsylvania counties were selected to test the 
hypothesis that the degree of urbanization influences the asthma hospitalization rate for adults.  
The study group was comprised of adults, 19-64 years, who were hospitalized for asthma (as the 
primary diagnosis) from 1999-2001.  To define urbanization related to traffic, daily vehicular 
traffic count and miles of roads/highways for each of the 6 counties were used.  We found, in 
some of the counties, a decrease in the adult asthma hospitalization rate as urbanization 
decreased.  However, for other counties, the rate increased as urbanization decreased.  The 
counties in which the latter was observed had depressed measures of socio-economic status 
(SES).  Our findings suggest that depressed socioeconomic conditions may supersede exposure 
to traffic-related pollution with respect to asthma hospitalizations.   
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3.1.3. Introduction 
 
 
It is estimated that 150 million people worldwide are living with asthma including 15 million 
people in the United States (Mannino et al., 2002). Asthma has been defined as a “chronic 
inflammatory disease of the airways that involves many cells and cellular elements” (National 
Institutes of Health Asthma Education and Prevention Program [NAEPP], 2002).  The 
inflammation is accompanied by increased airway hyper-responsiveness to a variety of 
environmental stimuli that include airborne allergens, viruses, tobacco smoke, and particulate 
matter (Etzel, 2003; Sotir, Yeatts, & Shy, 2003).  In Healthy People 2010, asthma is cited as a 
major clinical and public health problem (U.S. Department of Health and Human Services, 
2000).  One of the key objectives in the government document is reduction of environmental 
exposures that contribute to events associated with diminished lung function, such as asthma 
hospitalization.  
 
       Risk factors for asthma include:  
• Gender and prior diagnosis of allergies (Arif, Declos, Lee, Tortolero, & Whitehead, 
2003; National Center for Environmental Health [NCEH], 2003)    
• Communities with large populations and/or high household density (Crain et al., 2002)  
• Proximity to heavy traffic patterns, although the extent of their contribution to asthma 
hospitalizations is not known (English et al., 1999; Garshick, Laden, Hart & Caron, 2003; 
Kim et al., 2004) 
• Chronic exposure to nitrogen oxides and carbon monoxide which have been documented 
to exacerbate the inflammatory response in the asthmatic (Delfino, Gong, Linn, 
Pellizzari, & Hu, 2003; Ford et al., 2003; Gehring et al., 2002; Lin, Munsie, Hwang, 
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Fitzgerald, & Cayo, 2002; Nicolai et al., 2003; United States Environmental Protection 
Agency [U.S. EPA], 2005).   
 
       Traffic-related air pollution accounts for much of the diminished air quality seen especially 
in urban areas (Kunzli et al., 2003).  Although emission standards are regulated by the 
Environmental Protection Agency, traffic volume and type are not (U.S. EPA, 2005).  Heavy 
traffic patterns are a problem not only in large city centers, but also in areas of rapid suburban 
growth (Tibbetts, 2002).  Thus, traffic “corridors” are becoming more common irrespective of 
their proximity to pre-exiting communities (Lwebuga-Mukasa, Oyana, Thenappan, & 
Ayirookuzhi, 2004).  
 
       In the past decade, there has been a surge in adult asthma and associated complications.  The 
factors contributing to this increase are poorly understood although environmental factors of 
urbanization are suspect.  However, measurement of “urbanization” is difficult.   In the current 
study we assessed community urbanization by population size/density, the amount of vehicular 
traffic per day, and the total number of roads and highways.  We tested the hypothesis that the 
degree of urbanization of 6 Pennsylvania counties, as measured by these criteria, is an 
environmental risk factor for adult asthma hospitalization.  
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3.1.4. Methods 
 
Selection of counties                                  
The Pennsylvania counties selected for this study were Allegheny, Dauphin, Erie, Fayette, 
Lancaster, and York.  These counties were selected primarily as a sample of their varied 
distances to major urban centers.  We further typify urbanization by incorporating both 
population and motor vehicle characteristics of an urban community.  We used 4 measures: total 
population, population density (persons/mi2), miles of roads/highways, and daily vehicle miles 
traveled.  The population data were obtained from the 2000 Census published by the United 
States Census Bureau (United States Census Bureau [U.S. Census], 2000).  Traffic-related 
information, obtained from the Pennsylvania Department of Transportation, consisted of miles of 
roads/ highways and daily vehicle miles traveled in each county.  The counties were ranked for 
urbanization on a scale of 1-6 with respect to population size/ density, daily traffic density, and 
total miles of roads/ highways.  The overall urbanization rank of each county was determined by 
averaging the scores for each of the four measures.   The air quality of each county was 
evaluated using data contained in the Environmental Protection Agency’s Toxic Release 
Inventory (U.S. EPA, 2000).   
 
Case definitions 
 
Hospitalization data for adults aged 19-64 were obtained from the Pennsylvania Health Care 
Cost Containment Council (Pennsylvania Health Care Cost Containment Council, 2005).  During 
this three-year period, asthma (ICD code 493) was the primary diagnosis upon admission of 
3156 cases.  To control for patients hospitalized more than once during a calendar year, we 
utilized the patient identifier code (a randomly generated number unique to each individual in the 
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dataset).  Thus, only one event per patient identifier code was used for rate analysis.  The dataset 
also included demographic descriptors that allowed calculation of age-specific and gender-
specific asthma hospitalization rates. 
 
Data analysis  
Hospitalization rates/ 10,000 standardized to population data from the 2000 United States Census 
(U.S. Census, 2000) were determined for asthma causes.  Age-specific rates were calculated 
using the population counts also provided in the 2000 US Census.  To be consistent with age-
specific data published by the Centers for Disease Control, the population ages were stratified 
into 3 groups: 19-34, 35-44, and 45-64 yrs (NCEH, 2003).  Poisson regression analysis was used 
to assess statistically significant contributions to the adult asthma hospitalization rates by each of 
the independent covariates (county rank, gender, and age).  Previous studies have cited factors 
related to income and educational attainment as contributing to poor health outcomes 
(Boudreaux, Emond, Clark, & Camargo, 2003).  Since we did not have such data for the 
individuals in our study population, we employed graphical methods using EXCEL to describe 
the distribution of socioeconomic data for each county and the relationship of such data to adult 
asthma hospitalization rates within the county.  Statistical analyses were performed using 
STATA 8.0 and EXCEL for determination of relative risk.  All estimates of significance were at 
p = 0.05.  
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3.1.5 Results 
 
The degree of urbanization of each county was evaluated using the 4 measures described above.  
The results (table 1.1) indicate that ranks were consistent irrespective of the measure used.  
Allegheny County ranked first in each of the four categories.  Fayette County ranked sixth in 3 of 
the 4 categories, and ranked fifth in the category of miles of roads/highways.  
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Table 1.1.  Measures and rank of urbanization in the six Pennsylvania counties.   
 
 
 
 
a Average of the four measures of urbanization  
b Data obtained from the United States Census Bureau 
c Data obtained from the Pennsylvania Dept of Transportation
The rank of the county with respect to each measure of urbanization is shown in parenthesis 
County Overall 
ranka 
Total 
populationb 
 
 
Population 
densityb 
[persons /mi2] 
 
Miles of 
roads/ 
highwaysc 
 
Daily vehicle 
miles traveledc
 
Allegheny 1 1,270,612 
(1) 
1755 
(1) 
5688 
(1) 
25,154,896 
(1) 
Lancaster 2 474,601 
(2) 
496 
(2) 
3821 
(2) 
10,429,462 
(2) 
York 3 386,299 
(3) 
422 
(4) 
3691 
(3) 
8,462,878 
(3) 
Erie 4 279,636 
(4) 
350 
(5) 
2564 
(4) 
6,280,805 
(5) 
Dauphin 
 
4 251,316 
(5) 
479 
(3) 
1866 
(6) 
8,166,979 
(4) 
Fayette 6 147,367 
(6) 
188 
(6) 
2075 
(5) 
2,744,746 
(6) 
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       Age adjusted adult asthma hospitalization rates (x/ 10,000) for each county are shown in 
figure 1.1. The counties are ordered from left to right by decreasing rank of urbanization.   The 
hospitalization rate initially decreases with decreased urbanization, then increases as 
urbanization further decreases.  Fayette County, which ranked as the least urbanized county, had 
an asthma hospitalization rate greater than that of Allegheny County, the most urbanized county.  
 
 
 
Figure 1.1. Adult asthma hospitalizations in descending order of urbanization. 
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       Gender is recognized as a risk factor for asthma incidence and severity (Arif et al., 2003; 
Brogger et al., 2003).  We examined adult asthma hospitalization rates of males and females in 
each county (figure 1.2).  In all counties, females had higher hospitalization rates when 
compared with males.  In addition, an age-related trend of increasing hospitalizations was 
observed for females.   Using Poisson regression, urbanization, gender, and age were 
individually assessed for their contribution to adult asthma hospitalization rate within each 
county (table 1.2).  Results indicated that urbanization rank was not a significant contributor to 
the model (RR=1.04, p = 0.131).  However, gender (RR = 3.34, p = 0.0001) and age (RR = 1.17, 
p= 0.016) were each statistically significant.  A statistical model that included all 3 of the 
covariates was validated using a χ 2 goodness-of-fit test (χ 2 = 46.12, p=0.0518, r2 = 0.38) 
indicating the model is appropriate.  
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Figure 1.2. Age- X gender-specific rates in descending order of urbanization. 
 
 
 
 
 
Table 1.2.  Results of statistical analysis. 
  GOODNESS OF FIT 
FOR MODEL 
 
PSEUDO R2 
χ2= 46.02 
P= 0.05 
 
0.3793 
    
CO-VARIATE RELATIVE 
RISK 
p-VALUE CONFIDENCE 
INTERVAL 
Gender 3.34 0.0001 2.60-4.31 
Age group 1.17 0.016 1.03-1.33 
County rank 1.05 0.131 0.99-1.12 
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       Socioeconomic factors have been associated with the frequency of asthmatic attacks 
(Boudreaux, et al., 2003).  Although individual data for these factors were not available, 
aggregate data at the county level were obtained from the 2000 U.S Census (U.S. Census, 2000).  
The county-specific profiles of these factors in relation to the adult asthma hospitalizations are 
shown in figure 1.3, panels a-c.  There was a correlation between the hospitalization rate and the 
percentage of the population living below the federal poverty level (figure 1.3a).  An inverse 
relationship was observed for hospitalization and both median income and median property value 
(figure 1.3b, 1.3c).  Although low education has been cited as a risk factor for poor disease 
management, the profiles of educational attainment in the 6 counties were similar.  
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Figure 1.3a. By percent poverty Figure 1.3b. By median income 
Figure 1.3c. By median property value 
Figure 1.3. Indices of socioeconomic status and  
County-specific adult asthma hospitalization rates in  
descending order of urbanization 
 41
3.1.6 Discussion 
 
Traditionally regarded as a childhood disorder, in recent years asthma has emerged as a public 
health concern of adults age 19-64.  Unlike childhood asthma, adult asthma affects more females 
than males and tends to be more difficult to treat (Dolan et al., 2004).  
 
       Abundant roads and highways to accommodate heavy traffic often characterize an urban 
community.  Most studies that address the relationship of this urban characteristic with the 
frequency and severity of asthma symptoms have focused on children (Nicolai et al., 2003).  For 
example, (Kim et al., 2004) the proximity of roads to schools, and their relationship with asthma 
symptoms.  The authors found spatial variability in traffic related pollutants and an influence of 
this variability on the frequency of asthma symptoms in children.  
 
       Previous studies have shown that emissions from trucks is more detrimental than car 
emissions with respect to respiratory symptoms (Janssen et al., 2003; van Vliet et al., 1997).  We 
were able to obtain vehicular traffic count, the Pennsylvania Department of Transportation 
(Pennsylvania Department of Transportation, 2004).  Previous studies have noted a disparate 
prevalence of  commercial trucking routes in geographical areas with low SES (Brown et al., 
2003; Lwebuga-Mukasa et al., 2004).  This may explain why Fayette County, an area 
characterized as least urban, but with low SES, had the highest adult asthma hospitalization rate.   
 
       EPA collects and monitors information regarding the geographic distribution of facilities 
that release known respiratory irritants and toxins (U.S. EPA, 2000; White, Berger-Frank, 
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Middleton, & Falk, 2002).  In addition, prevailing wind patterns in the area of the emission 
sources contribute to reduced air quality (Peled et al., 2005).  Using geographical information 
systems (Nuckols, Ward, & Jarup, 2004; Vine, Degnan, & Hanchette, 1997), this information 
can be visualized for the Commonwealth of Pennsylvania (figure 1.4a and figure 1.4b).  
However, because we did not have the home addresses of our study population, our ability to 
assess the relationship between pollutant releases and individual health outcomes was limited. 
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Figure 1.4. The locations of industrial releases within our study sites.      
Figure 1.4a. Prevailing wind direction and locations of EPA-TRI facilities in the study area and 
neighboring states 
Figure 1.4b. Prevailing wind direction and locations of SO2 releasing  facilities in the study area 
and neighboring states 
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Epidemiological studies have suggested that a rural environment confers protection against the 
development of childhood asthma (von Mutius, 2001).  More recent reports from China and 
Europe have indicated a reduction in the prevalence of childhood asthma in rural settings (Chan-
Yeung et al., 2002; Waser et al., 2005).  This “hygiene hypothesis” suggests that exposures from 
farming and livestock tend to protect children from the development of asthma.  We did not 
observe a protective effect of a farming environment for adult asthmatics.  Lancaster County and 
Erie County both have substantial agricultural industry, yet their adult asthma hospitalization 
rates were substantially different.  
 
       Increased asthma morbidity in adult females has been reported (NAEPP, 2002).  We found 
asthma hospitalization rates in all 6 counties were higher for females than for males.  This is 
reflective of the National Institutes of Health’s report that 61% of adult asthmatics are female. A 
recent European study found that females, regardless of their geographic location, had higher 
indices of chronic disease severity than males (ENFUMOSA, 2003).  Biological mechanisms, 
such the endocrine shift during the menstrual cycle, or menopause, have been suggested to be 
responsible for this gender disparity (Haggerty, Ness, Kelsey, & Waterer, 2003; Vrieze, Postma, 
& Kerstjens, 2003).  It has also been hypothesized that the health seeking behavior of women, 
when compared with men, may explain gender disparities in chronic disease (McCance-Katz, 
Carroll, & Rounsaville, 1999; Meyer-Weitz, Reddy, Van den Borne, Kok, & Pietersen, 2000).  
Further cohort studies are needed to gain a better understanding of the gender disparity in adult 
asthma hospitalization rates.  
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       Age has been identified as a risk factor for asthma complications in adults (Bellia et al., 
2000).  We found that older adults (45-64 years) were 1.2 times more likely to be hospitalized 
for asthma than younger adults.  This finding is consistent with a report that older adults tend to 
have more difficulty managing their asthma (NAEPP, 2002).  It is unclear if the age-related trend 
is due to the age at disease onset or the duration of disease in an individual (Burrows, Barbee, 
Cline, Knudson, & Lebowitz, 1991; Busse, Banks-Schlegal, & Wenzel, 2000; Lange, Parner, 
Vestbo, Schnohr, & Jensen, 1998; Peat, Woolcock, & Cullen, 1987).   
 
       There were some limitations to our study.  The first was a lack of individual data related to 
socioeconomic status, educational attainment, environmental exposure and behavioral risk 
factors (i.e., smoking).  Variability between individuals in each county or between counties was 
not assessed.  These limitations are inherent in epidemiological studies that are ecological since 
such studies consider group characteristics when assessing an association between exposure and 
disease process (Gordis, 2000).  Another limitation was the absence of information related to 
healthcare coverage and use of preventive health services.  Such information would be useful for 
assessing the utilization of primary health care services for asthma management as opposed to 
seeking care only in acute situations.  
 
       This study is the first to address measures of urbanization and the influence of urbanization 
on adult asthma hospitalization rates.  The Commonwealth contains areas with high population 
density and others with low population density.  It also has a stable population that tends to 
relocate infrequently.  This stability is important when assessing the change over time in 
hospitalization frequency.  The unexpected trend of increased hospitalization with decreasing 
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size of the populace and decreased urbanization suggests a strong influence of demographic and 
socioeconomic factors.  These factors should be further explored to better understand their 
influence on human respiratory health.  
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3.2.1 Preface 
 
The prevalence of local asthma morbidity is not quite known.  Although estimates are provided 
by the CDC, local surveillance does not exist.  Here we examine the utility of local adult asthma 
hospitalization data as a source for surveillance.  We demonstrate that these data are useful not 
only to assess the baseline prevalence of asthma morbidity in Allegheny County but also as an 
environmental health indicator (as described by the Centers for Disease Control).  
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3.2.2 Abstract 
 
Objective We sought to evaluate the use of local hospital discharge data as an environmental 
health indicator.  Using these data, the demographic, temporal, and geographic distribution of 
adult asthma hospitalizations in Allegheny County were assessed. 
 
Methods: Asthma hospitalization data from 1999-2001 were obtained for adults 19-64 years.  
Hospitalization rates for demographic subgroups were assessed and compared with those 
published by the CDC. Daily hospitalization frequencies were assessed for a temporal 
relationship with the EPA’s daily Air Quality Index (AQI). Using the patient’s zip code of 
residence, ARC-VIEW GIS software was employed to visualize the geographic distribution of 
rates.  
 
Results: The adult asthma hospitalization rates were comparable to rates published by the CDC.   
The relationship between the daily hospitalization frequencies and the daily AQI was not 
statistically significant.  However, the geographic distribution analysis revealed 14 zip codes, 
primarily in the Southeast quadrant of the county, where elevated adult asthma hospitalization 
rates were statistically significant. 
 
Conclusion: A geographic-specific risk was identified for adult asthma hospitalizations. 
Continued evaluation of such of data as an environmental health surveillance tool is suggested.   
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3.2.3 Introduction 
 
One goal of Healthy People 2010 is to improve the surveillance of environmentally-related 
disease through the use of environmental health indicators (U.S. Department of Health and 
Human Services, 2000). Environmental public health indicators (EPHIs) can be used to assess a 
population’s health or risk of disease as it relates to the environment (C. f. D. C. National Center 
for Environmental Health, 2005).  Indicators can also be used to assess the baseline prevalence 
of disease and to build core surveillance capacity in state and local agencies.  There are 4 
categories of EHPIs.; hazard indicators, exposure indicators, health effect indicators, and 
intervention indicators.  EPHIs are further categorized into 3 tiers; core, optional, and 
developmental.   Core indicators are those regularly used by state agencies for environmental 
health surveillance.  Optional and developmental indicators encompass those that may be 
developed for future use or for intervention purposes.   The CDC has categorized asthma 
hospitalizations as a core health effect EPHI indicating the importance of the indicator and its 
measure with respect to policy or program considerations.  
 
       Asthma currently affects 14 million people in the United States (Mannino et al., 2002). Total 
direct medical expenditures for asthma care in the US are estimated to be in excess of $14 
billion, not including indirect costs such as lost work days (Weiss & Sullivan, 2001). Although 
the prevalence of asthma has increased worldwide, the etiological factors with respect to 
pathophysiology remain uncertain (S. Holgate, 2001). In addition, environmental factors that 
influence the prevalence asthma hospitalizations are poorly understood (S. T. Holgate, 1999). 
Asthma research has traditionally focused on children and the elderly, two populations 
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considered the most susceptible to complications, with little focus on adults 19-64 years.  
However, the prevalence of asthma in the latter group is gaining recognition as a formidable 
clinical and public health problem. 
   
       Studies have shown that outdoor air pollutants can trigger asthma symptoms (Delfino et al., 
2003; McConnell et al., 2002). The profiles of outdoor air pollution are seasonal. Particulate 
matter (PM) and ozone (O3) are primary air pollutants during the winter and the summer months, 
respectively (United States Environmental Protection Agency, 2005).   Although the technology 
is improving for daily monitoring of PM, particularly for PM< 2.5μm, studies assessing the 
health impact of this criteria pollutant are few.     
 
       The geographic distribution of environmentally-related disease, including numerous cancers, 
has garnered increasing attention in public health (Olden & White, 2005; White et al., 2002).  Of 
particular interest is the relationship between the exposure to elements in the environment (ie. 
poor air quality, prevalence of industrial facilities) and disease prevalence .  With the advent of 
new technologies, such as mapping software, studies investigating the incidence and prevalence 
of disease as it relates to the environment are possible (Nuckols et al., 2004; Vine et al., 1997).  
     
       To be consistent with the CDC’s Environmental Public Health Indicator project, we 
employed local hospital discharge data to assess the rates and frequencies of adult asthma 
hospitalizations.   We used this core indicator to investigate the baseline prevalence of adult 
asthma morbidity in Allegheny County, Pennsylvania.    
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3.2.4 Methods 
 
Dataset 
Hospital discharge data were obtained from the Pennsylvania Cost Containment Council 
(Pennsylvania Health Care Cost Containment Council, 2005). The population of interest was 
adults 18-64 years of age (N=2082) from Allegheny County, Pennsylvania who had been 
hospitalized for asthma (ICD 493.0-493.9) between 1999-2001.  Included in this dataset were the 
patient’s age, gender, race, and zip code of residence.   
 
Demographic-specific rate calculations   
For the calculation of hospitalization rates, the year 2000 was selected since it coincided with the 
2000 U.S. Census.  Age-adjusted and age-specific adult asthma hospitalization rates were 
calculated, including rates stratified by gender and race.  Race-specific rates were calculated only 
for Caucasians and African Americans since other races and ethnicities in Allegheny County 
make up less than 3% of the total population.  Age-specific rates were stratified by the same age 
groups used by the CDC (18-44 and 45-64 years).  The standard population used for age-
adjustment was obtained from the 2000 US Census (U.S. Department of Commerce, 2002).  The 
unique patient identifier code enabled us to control for individuals who had multiple hospital 
admissions for asthma within one calendar year.  
 
Temporal assessment of hospitalization frequencies 
A relationship between daily asthma hospitalization frequencies and daily air quality was 
assessed for the 3 year period. The Environmental Protection Agency’s (EPA) Daily Air Quality 
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Index (AQI) is an approximate indicator of overall air quality within a geographic area (U.S. 
Environmental Protection Agency, 2005a).  The criteria pollutants used to calculate the AQI 
include: carbon monoxide, nitrogen dioxide, ozone, sulfur dioxide, particulate matter < 2.5 μm 
(PM2.5), and particulate matter < 10 μm(PM10).  A daily index value is calculated for each 
criteria pollutant that is measured.  The AQI represents the highest of these indices and the 
corresponding pollutant is referred to as the “main pollutant”.   A relationship between the daily 
hospitalization frequencies and the daily main pollutant was further investigated.  For statistical 
analysis, AQI and hospitalization data over the 3-year period was pooled.   
 
Geographic specific rate calculations 
Using the subject’s zip code of residence, the geographic distribution of adult asthma 
hospitalizations was examined.  Subgroups were stratified by age, gender, and race. Of 
Allegheny County’s 89 zip codes, only 56 had “stable” populations which were extracted for 
analysis of geo-specific adult asthma hospitalization rates.  The measure of comparison was to 
the rates published by the CDC.  In addition, standardized incidence ratios (SIR) with 
corresponding confidence intervals (CI) were calculated.  Statistical significance was determined 
when a zip code’s SIR was > 100 (the null value) and the corresponding confidence interval did 
not include 100.      
 
The contribution of zip code-specific characteristics to asthma hospitalization rates 
Since individual patient characteristics related to socioeconomic status (SES) and environmental 
exposures were not provided in the dataset, we sought to assess the influence of area 
characteristics on adult asthma hospitalization rates. After zip code-specific rates were calculated 
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(as described in the preceding methods section), each of Allegheny County’s 89 zip codes was 
stratified as follows: 
1= Adult asthma hospitalization rates at or below that reported by CDC 
2= Rates higher than those reported the CDC but not statistically significant and   
3= Rates higher than those reported the CDC elevated and statistically significant  
 
A relationship of select zip code-specific characteristics to the aforementioned stratification 
assignment was assessed.    These characteristics included socioeconomic status (SES) and the 
prevalence of industrial facilities listed on the EPAs Toxic Release Inventory (TRI) (U.S. 
Environmental Protection Agency, 2005b).  Using logistic regression analysis, the influence of 
selected geographic factors on a zip code’s stratification assignment was evaluated.   
 
Statistical analysis 
Distribution analysis was visualized using MS-EXCEL.  Geographic distributions of adult 
asthma hospitalization trends within Allegheny County were visualized using the mapping 
software ARC-VIEW GIS 9.0.  For modeling of zip codes characteristics where rates were 
observed to be higher than expected, multivariate logistic regression was used to assess their 
relationship (STATA Corp. College Station, TX).  Exponentiated coefficients of these 
relationships are represented as odds ratios.  All estimates of significance were at the level 
p=0.05.   
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3.2.5 Results 
Demographic distribution of rates  
When compared with the nation al trends published by the Center’s for Disease Control (CDC) 
(National Center for Health Statistics, 2005),  the rates for all adults, adult males and adult 
females in Allegheny County were lower (figure 2.1a).  Although the local race-specific profiles 
were comparable to those reported by the CDC, there was a slight increase for Black females and 
a slight decrease for White females (figure 2.1b).   Age-group specific rates stratified by race and 
gender were similar to the CDC’s rates except for those of Black females which were noticeably 
higher in the age group 18-44 years and lower in Black males 45-64 years (figures 2.1c and 
2.1d).    
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Figure 2.1.Total and gender-specific adult asthma hospitalization rates. The rates shown are comparable to the CDC estimates (1a). 
Age-adjusted rate comparisons suggest a disparity amongst African-American females (1b), and more specifically in the age group 18-44 
years (1c).    
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Temporal distribution 
 
 
Adult asthma hospitalization frequencies were stable for the years 1999, 2000, and 2001 (748, 
703, and 631 respectively).  Daily adult asthma hospitalization frequencies for the 3-year period 
were assessed for a relationship to the daily Air Quality Index that is published by the EPA 
(figures 2.2 a, 2.2b, and 2.2c).  A consistent pattern was apparent of fewer hospitalizations on 
days when the AQI was higher (a threat to human health) and higher hospitalizations on days 
when the AQI was lower (not a threat to human health).  However, pooled data analysis for the 
3-year period revealed that the relationship was not statistically significant (OR= 1.0, CI= .994 - 
1.00, p=0.30).   Further pooled analysis of the relationship between hospitalization frequencies 
and the daily main pollutant indicated a positive correlation for days when the main pollutant 
was PM10 (OR= 1.87, CI= 1.47 - 2.39, p<0.001), and an inverse correlation for days when the 
main pollutant was ozone (OR = 0.685, CI = 0.515 - 0.912, p=0.009).  For the days when the 
main pollutant was PM2.5 and sulfur dioxide, there was not a relationship of hospitalization 
frequency with the main pollutant.   
 63
y Q
0
4
8
12
1/1
/19
99
1/3
1/1
99
9
3/2
/19
99
4/1
/19
99
5/1
/19
99
5/3
1/1
99
9
6/3
0/1
99
9
7/3
0/1
99
9
8/2
9/1
99
9
9/2
8/1
99
9
10
/28
/19
99
11
/27
/19
99
12
/27
/19
99
#
 
o
f
 
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
s
0
50
100
150
200
250
D
aily A
ir Q
uality Index (source E
PA
)
.Daily adult asthma hosp
daily AQI 1999
0
2
4
6
8
10
12
1/1
/20
00
1/3
1/2
000
3/1
/20
00
3/3
1/2
000
4/3
0/2
000
5/3
0/2
000
6/2
9/2
000
7/2
9/2
000
8/2
8/2
000
9/2
7/2
000
10/
27/
200
0
11/
26/
200
0
12/
26/
200
0
#
 
o
f
 
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
s
0
20
40
60
80
100
120
140
160
180
D
aily A
ir Q
uality Index ( source:EPA)
Daily asthma hosp
Daily AQI 2000
 
 
0
2
4
6
8
10
12
14
16
1/1/2001 3/2/2001 5/1/2001 6/30/2001 8/29/2001 10/28/2001 12/27/2001
D
a
i
l
y
 
a
d
u
l
t
 
a
s
t
h
m
a
 
f
r
e
q
.
0
20
40
60
80
100
120
140
160
180
D
aily A
Q
I ( source: EPA)
.Daily adult asthma hosp
Daily AQI 2001
2.2a. Profile for 1999 
2.2b. Profile for 2000 
2.2c. Profile for 2001 
Figure 2.2.  The relationship between daily Air Quality 
Index (AQI) and daily adult asthma hospitalizations 
The daily AQI is represented by the solid black line and 
daily adult asthma hospitalization frequency, represented 
by the gray shaded area, is shown for the years 1999-2001.  
The EPA calculates the AQI for the five major air 
pollutants regulated by the Clean Air Act: ground-level 
ozone, particle pollution (also known as particulate 
matter), carbon monoxide, sulfur dioxide, and nitrogen 
dioxide. The higher the AQI value, the greater the level of 
air pollution and health concern. 
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Geographic distribution 
 
 
Adult asthma hospitalization rates were calculated for each of the county’s zip codes.  Of the 
county’s 89 zip codes, 32 had hospitalization rates that were higher than those published by the 
CDC.  Of these, 16 had rates that were statistically significant (p=0.05) (figure 2.3).  This 
included rates for subgroups stratified by gender, age, and race. The majority of the zip codes 
with elevated rates are located within the southeastern quadrant of the county. 
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Figure 2.3. The distribution of adult asthma hospitaliziation rates by zip code.  The light 
pink areas represent zip codes where the adult athma hospitalization rates were equal to or less 
than of Allegheny County as a whole.  The mauve shaded areas represent zip codes where rates 
were elevated but not statistically significant. The red shaded areas represent the zip codes where 
rates were elevated and were statistically significant. 
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Assessment of the contribution of zip code-specific characteristics  
 
As described in the method section, each zip code was stratified based on their respective adult 
asthma hospitalization rates.    Zip code-specific characteristics were selected for assessment of 
their relationship to the hospitalization rates. The characteristics included those related to 
income, demographics, educational attainment, and the prevalence of industry.  The results of 
multinomial logistic regression analysis are shown in table 2.1.  Of the select area characteristics 
(n=10), 3 were statistically significant risk factors.   These were % of African Americans (OR= 
1.15, CI= , p=0.002),   % living below the poverty level (OR=1.20, CI= , p<0.001) and % of 
individuals with less than a high school education (OR=1.10 , CI= , p=0.023).  Neither the 
number of industrial facilities within a zip code nor their total amount of emissions (per year) 
showed a relationship to adult asthma hospitalization rates.  
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Table 2.1. Zip code-specific characteristics that were assessed for their influence on the 
respective adult asthma hospitalization rates.   
 
Area Characteristics Relative risk p-value 
% of African-Americans  1.15 0.002 
Percent living below federal 
poverty guidelines 
1.20 < 0.001 
< High school education 1.10 0.023 
Median income 1.0 
 
0.001 
Median property value 1.0 0.003 
High school education or GED 1.01 0.664 
Some college 1.03 0.684 
Bachelor’s degree and beyond  0.968 0.159 
Total # of facilities listed on the 
EPA’s TRI database  
1.05 0.791 
Total lbs. of emissions released 
into the air by facilities listed 
on the EPA’s TRI database   
1.0 0.361 
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3.2.6 Discussion 
 
 
For the past decade, evidence supporting the disproportionate distribution of environmentally-
related disease amongst the US population has increased (Gold & Wright, 2005; Olden & White, 
2005).   However, prospective surveillance of such has yet to be developed and utilized on a 
regular and timely fashion.  Healthy People 2010, the US Department of Health and Human 
Service’s program for addressing health disparities has prioritized the reduction of exposures that 
contribute to the etiology of environmentally-related disease (U.S. Department of Health and 
Human Services, 2000).   
 
       Currently, the Centers for Disease Control’s (CDC) Behavioral Risk Factor Surveillance 
Survey (BRFSS) is the most frequently utilized tool to estimate baseline prevalence of chronic 
disease in the US (Centers for Disease Control, 2005a).  This random-number telephone survey 
samples populations periodically for incidence and prevalence of disease.  Changes in such 
prevalence over time are often published by the CDC in their Morbidity and Mortality Weekly 
Report (MMWR) (Centers for Disease Control, 2005b).  However, since these estimates are at 
the national level, the CDC encourages local adaptation of the BRFSS. State and local agencies 
have adopted the BRFSS to address local public health issues but the BRFSS is rarely used by to 
estimate the local prevalence and morbidity of chronic disease. 
 
       Recently, the CDC has established a program tasked with developing local surveillance 
capacity for environmentally-related disease (C. f. D. C. National Center for Environmental 
Health, 2005).    The Environmental Public Health Indicator (EPHI) project aims to develop this 
capacity by identifying indicators of environmental health. The long-term goal is to incorporate 
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the local surveillance of the prevalence and morbidity of non-infectious chronic diseases into a 
national public health surveillance system.    
 
       One index of chronic disease prevalence and morbidity that has been cited in the CDC’s 
MMWR is hospital discharge statistics (C. f. D. C. National Center for Health Statsitics, 2005).  
The National Center for Health Statistics at the CDC regularly collects these data via a sample 
survey of hospitals in the US.  As a health effects indicator, the CDC has recognizes the utility of 
hospitalization data as a source to detect unusual patterns of events specific to environmentally-
related disease.   One such disease is asthma.  
 
       Asthma is a chronic respiratory disease whose etiology is suspected of being 
environmentally-related (Allacci, 2005; S. Holgate, 2001; S. T. Holgate, 1999).  In the past 
decade the incidence of newly diagnosed asthma has decreased,  the prevalence of   persistent 
asthma symptoms has increased (Lawson & Senthilselvan, 2005).  Although many studies have 
published that address the risk factors for childhood asthma, the risk factors for adult asthma 
remain poorly defined (Bel, 2004).  In addition, the prevalence of adult asthma morbidity is 
believed to be greatly underestimated (W. Busse et al., 2004; National Institutes of Health 
Asthma Education and Prevention Program, 2002).   Here we report the utilization of local adult 
asthma hospitalization data as an  environmental health indicator in Allegheny County., 
Pennsylvania which includes the city of Pittsburgh.  These data include all hospitalizations at all 
health care facilities within the county.  
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       The total adult asthma hospitalization rate for Allegheny County was comparable to the 
CDC’s latest estimates (National Center for Health Statistics, 2005).  Although the risk factors 
for adult asthma morbidity include female gender, current age, and race/ethnicity (Apter, 2003),  
comparable profiles were observed for both gender-specific and age specific rates.  However, the 
race-specific rates for African –Americans were slightly elevated.  This suggests the possibility 
of a greater burden of adult asthma hospitalizations in Blacks even though their percentage of the 
total Allegheny County population is about equal to that in the US and in the Commonwealth.   
 
       Most studies investigating the temporal distribution of asthma events have focused on the 
daily ambient air quality (Galan et al., 2003; Neidell, 2004; Wilson et al., 2005).  Air quality in 
the US is based on the concentrations of criteria air pollutants as defined by the Environmental 
Protection Agency (EPA) (United States Environmental Protection Agency, 2005).  The criteria 
pollutants are defined as such due to their harmful effects to human health.  They include sulfur 
dioxide (SO2), nitrogen dioxide (NO2), carbon monoxide (CO), ozone (O3), and particulate 
matter <10um (PM10) and <2.5um (PM2.5).  The EPA’s daily Air Quality Index (AQI) is 
reflective of the concentrations of the main pollutant on the day of interest; the higher the index, 
the poorer the air quality.  With respect to health effects, the most investigated pollutant is ozone.  
Published studies have shown the adverse effects of ozone even in healthy individuals 
(McConnell et al., 2002; Mudway & Kelly, 2004).   
 
       Our study showed that on days of increased adult asthma hospitalizations, the air quality 
index was lower (i.e. better air quality).  In addition, the main pollutant on these days was not 
ozone but particulate matter.  Further assessment of the relationship of the daily main pollutant 
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and hospitalization frequencies demonstrated identified a positive correlation of PM10 and an 
inverse correlation of ozone.  These results differ from studies investigating the effects of ozone 
on child asthma hospitalizations (Farhat et al., 2005).  However, numerous studies have cited a 
relationship between respiratory and cardiopulmonary hospitalizations on or about days where 
PM is the main pollutant (Delfino et al., 2005; Kappos et al., 2004; Ruidavets et al., 2005; 
Thurston & Bates, 2003).  An explanation could be that the severe form of asthma, which is 
found more often in adults,  is characterized by higher degree of lung obstruction due to 
remodeling rather than airway hyper-responsiveness (Bai & Knight, 2005; S. Wenzel et al., 
2005).  Another explanation may be that the influence of seasonal bacterial respiratory infections 
on adult asthma morbidity.  Although the sero-prevalence of pathogens responsible for 
pneumonia is higher in asthmatics, the age-specific effect has yet to be delineated(Johnston & 
Martin, 2005).   
 
       The impact that the environment has on health effects and disease prevalence is frequently 
cited within the context of environmental justice.  One tenet of environmental justice is that 
individuals must have control over exposures in their environment (Apelberg et al., 2005; Brulle 
& Pellow, 2005; Gee & Payne-Sturges, 2004).  Since our dataset included the patient’s zip code 
of residence, we assessed the influence of zip-code specific characteristics such as poverty and 
the prevalence of industrial facilities on the respective rates.  We found an elevated risk of adult 
asthma hospitalization associated with factors of SES such as poverty and lower educational 
attainment.  The 14 zip codes with higher rates, located predominantly in the Southeastern 
quadrant of the county, also had higher percentage of African-Americans residents.   In addition, 
indices of exposure to industrial sites were not statistically significant.   However, since the exact 
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address of patients in this study were not available, further quantification of exposure effects was 
not possible.   
       There were limitations to this study primarily related to personal information regarding the 
cohort.  The lack of individual addresses for the patients did not allow further analysis of 
exposures due to factors such the regional prevalence of power plants and incinerators.  These 
data when accompanied by wind direction and residential addresses have shown compelling 
results with respect to health effects due to exposure (Peled et al., 2005; Villeneuve et al., 2005).  
In addition, personal medical history with respect to asthma (i.e. age of onset, health care 
delivery and access) are often cited as risk factors for asthmatic adults who have poor control of 
the disease (Adams et al., 2003).  Finally, personal habits related to tobacco smoke exposure and 
daily exposure to traffic-related pollution have been associated with airway hyper-responsiveness 
in both asthmatics and non-asthmatics (Lwebuga-Mukasa et al., 2005).    
 
       We have shown that hospitalization data that includes all health care facilities are a useful 
tool for estimating disease morbidity within a community.  The Commonwealth of Pennsylvania 
is only one of three states within the US that collects such data.  The timeliness and availability 
of the data adds to its utility of being used in the capacity of an environmental health indicator.   
 
       This is the first study to estimate the burden of asthma morbidity within Allegheny County, 
PA using the criteria set forth by the CDC for environmental health surveillance.  Such 
surveillance is necessary so that temporal or geographic changes over time may be detected. By 
developing this environmental health capacity, meaningful and appropriate public health 
interventions can be implemented.   
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3.3.1. Preface  
 
Currently, biomarkers that identify risk of asthma symptoms does not exist.  With respect to 
environmental exposures, characteristics within our daily environment have been identified as 
risk factors for asthma symptoms (ie. environmental tobacco smoke, ozone, respiratory 
infection).  However, estimating the threshold that asthmatics can tolerate these exposures 
without exacerbations is difficult without non-invasive prognostic biomarkers.    Here we assess 
the utility of serological biomarkers to assess the relationship of exposure to atypical respiratory 
pathogens and asthma severity classification in a clinical cohort of adult asthmatics.     
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3.3.2. Abstract 
 
 
Asthma currently affects 7.4 million adults in the United States. The phenotype of “severe” 
asthma affects approximately 10% of all adult asthmatics. Lack of uniformity in recognition of 
risk factors, diagnosis of severe asthma and treatment thereof are challenges for both patients and 
clinicians. Of particular interest is the risk conferred by atypical pathogens to the severe asthma 
phenotype.  The seroprevalence of biomarkers indicating infection by the atypical pathogens, 
Mycoplama pneumonia (Mpn) and Chlamydia pneumonia (Cpn), was assessed in a cohort of 
adult asthmatics as part of the Severe Asthma Research Project (SARP).  Participants (N = 215) 
were stratified according to disease severity as follows; mild/ moderate asthma  (n= 152) and 
severe asthma (n = 63).  With respect to disease severity, the risk conferred from infection with 
Cpn was not statistically significant (OR = 1.140, CI = 0.674 – 1.928, p =0.629).  However, the 
risk for Mpn infection was lower for the severe group and was statistically significant (OR = 
0.518, CI = 0.289 - 0.928, p=0.027).  Further characterization of the severe asthma group 
revealed a higher frequency of treatment with antibiotics for sinusitis ( OR = 2.741, CI =1.493 – 
5.034, p = 0.009) and high-dose corticosteroids with additional anti-inflammatory drugs ( OR = 
13.171, CI = 5.735 – 30.251, p < 0.0001).  The results suggest that the risk of severe asthma 
conferred by atypical pathogens may be modulated by the patient’s current asthma therapy which 
includes combination anti-inflammatory medication and concurrent treatment with antibiotics.  
Further investigation should include analysis of bronchial specimens and the delineation of 
concurrent antibiotic and anti-inflammatory drug therapy in this sub-population of adult 
asthmatics.  
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3.3.3. Introduction 
 
Asthma currently affects 7.4 million people over the age of 15 in the United States (Arif et al., 
2003; Mannino et al., 2002). Although asthma-specific mortality rates for this age group have 
decreased, the increasing number of hospitalizations and attacks continue to be a significant 
problem for adults (E. S. Ford et al., 2003).   The adult-onset asthmatic tends to have greater 
measures of morbidity (i.e. rapidly declining lung function) when compared with child-onset 
asthmatics (Bel, 2004).  Previous studies have also cited that the diminished lung capacity in the 
adult-onset asthmatic is not reflective of disease duration (Jenkins et al., 2003). Thus, it is 
believed that adult-onset asthma may be a distinct disorder.   
 
       The “severe” asthma phenotype of represents < 10% of all adult asthmatics although this 
group accounts for a disproportionate share of the $14 billion spent annually for asthma-specific 
direct medical care (W. W. Busse et al., 2000; Godard et al., 2002).  The lack of uniformity 
regarding the recognition of risk factors and diagnosis of severe asthma has been a clinical and 
public health challenge (National Institutes of Health Asthma Education and Prevention 
Program, 2002).  Risk factors for adult asthma such as female gender, age, and BMI have been 
cited in previous studies (Arif et al., 2003; Ellman et al., 1997).  However, their contribution to 
the severe phenotype is less understood.  In addition, there are few studies that investigate the 
extent to which host-environment interaction affects progression to severe asthma are few.  Of 
particular interest is how environmental biological agents, such as bacteria and viruses, 
contribute to the patho-physiology of adult severe asthma (Douglass & O'Hehir, 2000; 
Lemanske, 2003; Lemanske & Busse, 2003).   For example, recent studies have demonstrated a 
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relationship between respiratory viruses and frequency of asthma symptoms in asthmatic 
children (Gern & Lemanske, 2003).  However, for adult asthmatics this relationship has involved 
respiratory bacteria rather than respiratory viruses (Kraft, 2000).    
        
     One class of bacteria, atypical respiratory bacteria, is highly suspect as a risk factor in the 
pathogenesis of severe asthma (Blasi et al., 1998; P. J. Cook et al., 1998; Kraft, 2000; Martin et 
al., 2001).    Atypical respiratory bacteria is a term used to distinguish a group of bacteria (i.e. 
Chlamydia, Mycoplasma) from those such as streptococcus that are “typically” recognized as 
being responsible for respiratory infections (Hammerschlag, 2001, 2003).   Here we test the 
hypothesis that sero-prevalence of biomarkers indicating infection by Chlamydia pneumonia and 
Mycoplasma pneumonia is a risk factor for severe asthma in adults.   
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3.3.4. Methods 
 
Study cohort 
Subjects, age 15-68 years, were enrolled in the multi-city Severe Asthma Research Project 
(SARP) funded by the National Heart, Lung, and Blood Institute of the National Institutes of 
Health. Each city worked under a standardized definition of severe asthma (as defined by the 
SARP steering committee) and uniform inclusion criteria for severe asthma.  Patients who 
reported having been diagnosed with asthma were assessed for asthma severity based on the 
following criteria: 
 
Major criteria (individual must satisfy at least one of the following): 
• Treatment with continuous or near-continuous oral corticosteroids 
• Treatment with continuous high-dose inhaled corticosteroids 
 
Minor Criteria: (individual must satisfy at least two of the following) 
 
• Require daily treatment with controller medication in addition to inhaled corticosteriods 
• Asthma symptoms require short-acting β-agonist use on a daily or near daily basis 
• Persistent airway obstruction, as determined by FEV1 < 80% predicted and diurnal PEF 
variability > 20% 
• One or more urgent care visits for asthma per year 
• Three or more oral corticosteroid bursts per year 
• Prompt deterioration with reduction in oral or inhaled corticosteroid dose 
• Near-fatal asthma event in the past 
 
Asthmatic subjects who did not satisfy the above criteria for severe asthma were classified as not 
severe.  
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Data 
General.  Upon enrollment into the SARP, all qualified subjects were asked to sign a consent 
form that permits the sharing of their data and/or biological samples across the SARP study sites.    
 
Screening.  Prospective study subjects were screened for eligibility based on their smoking 
history, prevalence of respiratory disease other than asthma (i.e. Cystic Fibrosis and Vocal Cord 
Dysfunction), diagnosis with asthma, length of disease, asthma medication and attack history, 
and satisfaction of the aforementioned major and minor criteria for severe asthma.  
 
Serological analysis for respiratory pathogens.  Serum was obtained from study subjects for 
serological analysis of antibodies indicative of respiratory infection cause by Mycoplasma 
pneumoniae (Mpn) and Chlamydia pneumoniae (Cpn).  An Enzyme-Linked Immunosorbent 
Assay (ELISA) specific for the detection of Mpn- and Cpn-specific antibodies was used (Savyon 
Diagnostics, Ashdod, Israel). In addition to being assessed for the presence of Cpn or Mpn 
antibodies, the study subjects were assessed for the degree of infection as follows: IgM (current 
infection), IgG (past infection) and IgA (chronic infection).   
 
Clinical assessments  Blood drawn from all study subjects was assessed at each site laboratory 
for  white blood cell differentials, IgE, hematocrit, and hemoglobin.  Allergy skin testing was 
performed on all adult SARP study subjects. The protocol for the allergen skin test and panel of 
allergens used in the skin test was standardized across the 10 sites.  Spirometry or lung function 
measurements were used by the SARP to determine the severity of asthma in the study subjects.   
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Questionnaire.  Upon qualification for study enrollment, the participant was asked to complete 
the self-administered SARP questionnaire.  These sections included: 
• Asthma-specific quality of life 
• Atopy history 
• Demographic information 
• Environmental factors specific to pet ownership 
• Family allergy and asthma history 
• General symptoms of respiratory disease 
• Medical history, including co-morbidities and health care utilization 
• Medication history 
• Provoking factor exposure specific to asthma symptoms 
• Smoking and ETS exposure history 
• Symptoms and exposures exclusive to women (i.e. reproductive, hormones). 
 
 
Statistical analysis 
Controlling for confounding variables. Based on the recent literature regarding risk factors for 
adult asthma severity, current age and female gender were selected as variables that were 
controlled.  Since recent evidence suggests that a person’s body mass index (BMI) may 
contribute to poor health outcomes in those with chronic disease, BMI was also selected (E. S. 
Ford, 2005).   At the time of this analyses, the SARP cohort was limited in the racial/ ethnic 
makeup.  Therefore, we were not able to control for race/ ethnicity. 
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Logistic regression. The goal of logistic regression is to correctly predict the category of 
outcome for individual cases by  finding the best fitting model to describe the relationship 
between the dependent variable (i.e severe asthma)  and a set of independent (predictor or 
explanatory) variables (Friese and Long, 2003; Rosner, 2005). Logistic regression generates the 
coefficients (and its standard errors and significance levels) of a formula to predict a logit 
transformation of the probability of presence of the characteristic of interest: 
 
where p is the probability of presence of the characteristic of interest. The logit transformation is 
defined as the logged odds or odds ratio: 
                                            
 
 
 
Univariate analysis.  Using logistic regression, all variables were assessed individually for their 
relationship to severe asthma.  Those with a p-value <  0.15 were extracted and retained for 
further stepwise regression analysis.  
 
Stepwise “backward” regression analysis and severe asthma model.  Stepwise regression is a 
form of logistic regression that tests the fit of the model after individual variables are added or 
deleted and is used to explore the relationship of predictor variables to the outcome of interest.  
Backward stepwise regression is the analysis that begins with a full or saturated model and 
variables are deleted from the model in an iterative process. The fit of the model is tested after 
Odds ratio =       p     =    probability of presence of character                
                            1  - p          probability of absence of characteristic 
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the elimination of each variable to ensure that the model still adequately fits the data. When no 
further variables can be eliminated from the model, the analysis has been completed.   In all 
cases, the p-value criteria for entry into the model must be less than for its removal.  Standard 
practice in epidemiology and biostatistics is p= 0.15 for entry of a predictor variable into the 
stepwise elimination model and p= 0.20 for removal (Friese and Long, 2003; Hosmer Jr. and 
Lemeshow, 2000).    
 
       The additional information collected from the SARP study subjects via a self- administered 
questionnaire and various clinical measurements were each assessed for statistical significance as 
a predictive variable.  Those variables whose p-value was 0.15 or less were extracted for 
multivariate analysis.  These variables were group into 6 sets and each set was analyzed using 
backward stepwise multivariate regression modeling while controlling for age, gender, and BMI.  
The resulting variables from each of the 6 sets were re-analyzed in a final model for asthma 
severity.  
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3.3.5. Results 
 
Descriptive characteristics of study cohort. 
Upon enrollment, the SARP study participants were categorized as normal/ no asthma (n = 18), 
mild/ moderate asthma (n = 152), or severe asthma (n = 53) (table 3.1).  The gender distribution 
across these 3 groups was similar with an approximate ratio of females to males 2:1.  The median 
age distribution and range of ages increased with disease morbidity regardless of gender.   BMI 
also increased with disease morbidity but was more noticeable in females.    
 
Table 3.1.  Descriptive characteristics of SARP cohort (n = 233).   
 
  
 
Normal 
N = 18  
 
Mild/moderate asthma 
N = 152  
 
Severe asthma 
N = 63  
Gender    
       Male                    
               # (%) 
 
7  (39) 
 
 43 (28.3) 
 
23 (36.5) 
       Female                
               # (%) 
 
11 ( 61) 
 
109 (71.7) 
 
40 (63.5) 
Age    
  
(median -range) 
 
25.9 (18.9 –49.0) 
 
30.8 (13.0 – 63.2) 
 
44.1 (16.7 -   68.1) 
       
     By gender 
   
                       
                  Male 
 
25.9 ( 22.5 – 42.4) 
 
28.4 (13.2 – 57.7 ) 
 
44.9 (22.1 – 66.5) 
                  
               Female 
 
24.3 (18.9 – 48.0) 
 
32.9 (13.0 – 63.2) 
 
43.8 (16.7 – 68.1) 
BMI    
  
median (range) 
 
26.7 ( 20.6 – 47.6) 
 
28.0 ( 17.4 – 63.9)  
 
30.0 (19.8 – 55.7) 
       
      By gender 
   
                     Male  
26.4 ( 23.9 – 47.6) 
 
26.4 (17.4 – 41.2) 
 
28.7 (20.1 – 45.0) 
                  Female  
27.0 ( 20.6 – 37.6) 
 
28.2 (17.8 – 63.9)  
 
31.3 (19.8 – 55.7) 
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Seroprevalence of  biomarkers and provocation of asthma symptoms 
During the SARP enrollment process, subjects had been asked if their asthma symptoms were 
provoked by respiratory infection (table 3.2).  Although a slightly larger percentage of severe 
asthmatics compared with mild/ moderate asthmatics responded “yes” to this question, the 
difference was not statistically significant (OR = 2.090, CI = 0.579 - 7.542).  Also shown in table 
3.2 is the results of the serological analysis that compared the prevalence of Mpn- and Cpn-
specific antibodies between the mild/moderate asthmatics and the severe asthmatics.  For the 
seroprevalence of Mpn –specific antibodies, severe asthmatics were at a decreased risk (OR = 
0.518, CI = 0.289 - 0.928, p= 0.027).  The severe group also exhibited an increased risk of 
testing positive for Cpn-specific antibodies but this observation was not statistically significant 
(OR = 1.140, CI = 0.674 - 1.928, p= 0.625).  With respect to degree of infection, past infection 
with Mpn was the most frequent finding in mild/moderate asthmatics and past/ chronic infection 
with Cpn was the most frequent finding in severe asthmatics.    
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Table 3.2. The seroprevalence of Cpn- and Mpn- specific antibodies between the 2 asthmatic groups.  In addition, results of 
univariate analysis with the respective odds ratios and corresponding confidence intervals and p-values are shown.  
 
  
Mild/moderate asthma 
N = 152  
# (%) 
 
Severe asthma 
N = 63 
# (%) 
 
Odds ratio (CI) 
 
p-value
 
Asthma provoked by respiratory infection   134  ( 91) 60  (95) 2.090 (0.579  -  7.542) 0.230 
Mycoplasma pneumonia +   subjects             89 ( 61.8) 31 ( 45.6) 0.518  (0.289  -  0.928) 0.027 
By degree of infection     
Current 3  ( 2.0) 3 ( 4.8) 2.162 ( 0.426 – 10.968) 0.352 
Past 49 ( 32.5) 19 ( 30.2) 0.728 9 0.397 – 1.334) 0.300 
Chronic 9  ( 5.9) 0 0.408 ( 0.087 – 1.909) 0.215 
Borderline 18 ( 11.8) 9 ( 14.3) 1.003 ( 0.431 – 2.333) 0.994 
Current / past 11  ( 7.2) 0 0.182 ( 0.023 – 1.434) 0.106 
Past / chronic 8  ( 5.3) 3 ( 4.8) 0.785 ( 0.202 – 3.046) 0.727 
Current / past / chronic 4  ( 2.6) 2 ( 3.2) 1.060 ( 0.190 – 5.916) 0.947 
     
Chlamydia pneumonia +     subjects            72 ( 50) 36 ( 52.9) 1.140  (0.674  - 1.928)  0.625 
By degree of infection     
Current 1    ( 0.7) 1 ( 1.6) 2.000 ( 0.123 – 32.377) 0.629 
Past 26 ( 17.1) 14 ( 22.2) 1.391 ( 0.727 – 2.663) 0.323 
Chronic 10  ( 6.6) 0 0.189 ( 0.024 – 1.503) 0.115 
Borderline 0 1 ( 1.6) -------- ----- 
Current / past 3   ( 2.0) 0 -------- ----- 
Past / chronic 33  ( 21.7) 18 ( 28.6) 1.325 ( 0.725 – 2.421) 0.363 
Current / past / chronic 4   ( 2.6) 0 ------- ----- 
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Assessment of additional potential risk factors 
Additional information was collected from the SARP study subjects via a self- administered 
questionnaire and various clinical measurements (table 3.3).    As mentioned in the Methods 
section, variables that were statistically significant after univariate analysis were extracted, 
grouped into 6 sets (based on their respective relevance), and further analyzed using multivariate 
logistic regression.   
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Table 3.3. Additional SARP subject characteristics that were assessed for the risk of asthma severity.  
Category of factor Sample of factors 
 Allergy  (atopy) history Age of onset, seasonal symptom frequency, age allergy onset 
 Allergy skin test Mold, vegetation, cat, dog, dust mite 
Asthma history Yrs with asthma, age of onset 
Asthma quality of life measurements Domains include activity, emotions, environment stimuli, and asthma symptoms 
Asthma symptoms Frequency of cough, sputum, chest tightness, wheeze, shortness of breath, 
nocturnal breathing difficulty, use of rescue inhaler; duration of asthma attacks 
Blood analysis White blood cell differentials, Hemoglobin, Hematocrit 
Co-morbidities including respiratory and  
non- respiratory  
Pneumonia, acute and chronic bronchitis, sinusitis, sinus surgery, nasal polyps,  
polyp surgery 
Family history Asthma, allergies, eczema (father, mother, sibling, child) 
Female –specific factors Pre-menstrual symptoms, HRT, ovarian or uterine surgery 
Lung function test (Spirometry) FEV, FVC, PEF, FEF 
Medical care utilization Need for urgent care, doctor office visits, ED or hospitalization, ICU 
Medication use ICS and B-agonist use, need for rescue inhaler, additional controller meds 
Pet ownership Cat, dog, rodent, bird 
Provoking factors Animal, activity, exercise, aspirin 
Tobacco use and exposure Smoking status, including length and beginning age; exposure to environmental 
tobacco smoke  
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Symptom-frequency set. Study subjects were asked questions regarding both factors that provoke 
asthma attacks and the length of their asthma attacks.  Subjects were also administered an 
Asthma Quality of Life Questionnaire (used with permission from Dr. Elisabeth Juniper).  The 
results of univariate analyses are shown in table 3.4.    Backward stepwise regression resulted in 
the retention of provocation due to either exercise ( OR = 1.96 , CI= 0.82 – 4.70 ) or normal 
daily activity ( OR = 3.66 , CI =1.17–11.48 )  as risk factors for this set.         
 
 
 
Table 3.4. Symptom-specific risk model for severe asthma.  Shown are the significant risk 
factors after univariate analysis and those that remained after multivariate analysis 
 
 Univariate 
analysis  
 Multivariate 
analysis 
 
  
Odds ratio 
(Confidence 
interval) 
 
Global p-
value 
 
Symptom 
model 
OR 
 
Symptom 
model 
 CI 
Asthma provoked by 
routine physical 
activity 
 
3.30  
( 1.70 – 6.41) 
 
 
0.0002 
 
1.96 
 
0.82 – 4.70 
Asthma provoked by 
exercise 
 
3.08  
( 1.141 – 8.317) 
 
0.0140 
 
3.66 
 
1.17 – 11.48 
Asthma quality of 
life score 
 
1.60 
( 1.26 – 2.05) 
 
0.0001 
 
------- 
 
------- 
Duration of asthma 
attacks 
 
1.56 
( 1.155 – 2.107) 
 
0.0040 
 
------- 
 
 
------- 
Symptom frequency 
score 
 
1.09 
( 1.042 – 1.142)1 
 
0.0001 
 
------- 
 
------- 
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Health care utilization and medication use set. The need for urgent medical care and use of 
rescue and/or additional asthma medication was assessed.  For the severe asthma group, higher 
frequencies of unscheduled doctor appointments, emergency room visits, and hospital/ ICU 
admissions for breathing problems were all risk factors (table 3.5).  With respect to medication 
use, using a daily short acting beta-agonist inhaler and use of additional controller medication 
were identified as risk factors following univariate analysis.  After backward stepwise regression, 
seeing a doctor in the last 12 months ( OR = 3.53, CI = 0.89 – 13.92)  and ever having been 
admitted to an ICU due to breathing problems ( OR =3.11 , CI = 0.98 – 9.82 )  in addition to the 
use additional controller medications ( OR 4.63 = , CI =1.45 – 14.80) remained as risk factors 
within this model.  
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Table 3.5. Health care- and medication-specific model for severe asthma.  Shown are the significant risk factors after univariate 
analysis and those that remained after multivariate analysis 
 
 Univariate analysis  Multivariate 
analysis 
 
  
Odds ratio 
(Confidence interval) 
 
Global 
 p-value 
Health care/ 
medication 
Model 
OR 
Health care/ 
medication  
Model  
CI 
 
One or more urgent care visits in the last 12 
months due to breathing problems 
 
2.766 
 ( 1.572 – 4.865) 
 
0.0004 
 
------- 
 
------- 
 
Seen a doctor in the last 12 months due to 
breathing problems 
7.44 
 ( 3.32 – 16.68) 
 
< 0.0001 
 
3.53 
 
0.89 – 13.92 
 
ER ever for breathing problems 
 
2.17 
 ( 1.12 – 4.22) 
 
0.0180 
 
------- 
 
------- 
 
Hospitalization ever for breathing problems 
 
3.79  
( 2.05 – 7.03) 
 
< 0.0001 
 
------- 
 
 
------- 
 
Hospitalization last 12 months for breathing 
problems 
 
5.43 
 ( 1.39 – 21.31) 
 
0.0080 
 
------- 
 
------- 
 
ICU ever 
 
5.33  
( 2.28 – 12.46) 
 
0.0001 
 
3.11 
 
0.98 – 9.82 
 
Daily use of β -agonist inhaler 
 
4.70  
( 2.66 – 8.20) 
 
< 0.0001 
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Female-specific model.  Univariate analysis of surgical removal of the ovaries, surgical removal 
of the uterus, and current use of hormone replacement therapy resulted in inclusion of these 
factors for stepwise regression (table 3.6).  However, only current treatment with hormone 
replacement therapy ( OR = 9.95, CI = 1.91 – 51.8) remained in the female-specific model.  
 
 
Table 3.6. Female-specific model for severe asthma.  Shown are the significant risk factors 
after univariate analysis and those that remained after multivariate analysis 
 
  
Univariate 
analysis 
  
Multivariate 
analysis 
 
  
Odds ratio 
(Confidence 
interval) 
 
Global 
 p-value 
 
Female-specific 
Model 
OR 
 
Female-specific 
Model  
CI 
Surgical removal 
of the uterus  
 
2.55  
(0.927 – 7.039) 
 
0.076 
 
------- 
 
------- 
Surgical removal 
of the ovaries 
 
3.26  
( 1.13 – 9.40) 
 
 
0.032 
 
------- 
 
------- 
Currently on 
hormone 
replacement 
therapy 
 
13.81  
( 2.79 – 68.40) 
 
0.002 
 
9.95 
 
1.91 – 51.8 
 96
Comorbidity-specific model.  In addition to gastroesophageal reflux disease (GERD), all 
respiratory comorbidities that were assessed for a relationship to severe asthma qualified for 
inclusion in the stepwise model (table 3.7).  In the final comorbidity model, having been treated 
with antibiotics for sinusitis (OR = 1.72 , CI= 0.81 – 3.64), current GERD (OR = 3.27 , CI =1.43 
– 7.31 ), and ever having nasal polys (OR = 3.57 , CI =1.19 – 10.75 ) or pneumonia ( OR = 2.09 , 
CI =  0.99 – 4.44) remained as predictive factors for severe asthma.  
 
Table 3.7. Co-morbidity specific model for severe asthma.  Shown are the significant risk 
factors after univariate analysis and those that remained after multivariate analysis 
 
  
Univariate 
analysis 
  
Multivariate 
analysis 
 
  
Odds ratio 
(Confidence 
interval) 
 
Global 
 p-value 
 
Co-morbidity 
Model 
OR 
 
Co-morbidity 
Model  
CI 
Bronchitis treated with 
antibiotics 
 
1.66  
( 0.916 – 3.01) 
 
0.0940 
 
------- 
 
------- 
Gastroesophageal reflux 
disease (GERD) 
 
3.97 
 ( 2.06 – 7.65) 
 
< 0.0001 
 
3.27 
 
1.43 – 7.31 
Nasal polyps  
4.38 
 ( 1.78 – 10.76) 
 
0.0010 
 
3.57 
 
1.19 – 10.75 
Nasal polyp surgery  
5.88  
( 2.24 – 15.40) 
 
0.0002 
 
------- 
 
------- 
Pneumonia  
2.91  
( 1.58 – 5.36) 
 
0.0005 
 
2.09 
 
0.99 – 4.44 
Sinus surgery  
3.43  
( 1.64 – 7.17) 
 
0.0010 
 
------- 
 
------- 
Sinusitis treated with  
antibiotics 
 
2.74  
( 1.49 – 5.03) 
 
0.0009 
 
1.72 
 
0.81 – 3.64 
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Atopy- and inflammation-specific model.  Although severe asthmatics had lower reactivity to 
allergens applied during the allergy skin test, they reported higher frequency of seasonal specific 
symptoms.  This observation was reflected in the total seasonal atopy score that was a 
statistically significant risk factor after univariate analysis (OR =1.151, CI = 1.026 – 1.291) 
(table 3.8).  While the risk of serological indices for allergy (i.e. eosinophils, IgE) were elevated 
in the mild/ moderate group, the severe group had an elevated risk of   higher neutrophil counts, 
higher neutrophil percentage, and a higher hematocrit.   After stepwise regression, only the 
percentage of neutrophils and the total atopy score remained in the model specific for atopy and 
inflammation. 
 
 
 
Table 3.8. Atopy- and inflammation -specific model for severe asthma.  Shown are the 
significant risk factors after univariate analysis and those that remained after multivariate 
analysis.  
 
  
Univariate 
analysis 
  
Multivariate 
analysis 
 
  
Odds ratio 
(Confidence 
interval) 
 
Global 
 p-value 
 
Atopy/ 
inflammation 
Model 
OR 
 
Atopy/ 
inflammation 
Model  
CI 
Neutrophil ct 1.156  
( 0.964 – 1.387) 
0.117 ------- ------- 
Neutrophil % 1.029 
( 1.0 – 1.059) 
0.047 1.029 0.996 - 1.062 
Hematocrit 1.058 
 ( 0.979 – 1.143) 
0.151 ------- ------- 
Allergies make you 
breath worse             
5.8  
( 0.741 – 45.386) 
0.034 ------- ------- 
Total seasonal atopy 
score               
1.151  
( 1.026 – 1.291) 
0.014 1.269 1.099 - 1.465 
 98
Lung function-specific model.   Severe asthmatics were more likely to have a higher baseline 
forced expiratory volume (the amount of air forcibly expired in 1 second) as measured the FEV 1 
percent predicted (table 3.9).  However, this group was more likely to perform poorly when 
measured for forced vital capacity (the amount of air forcibly expelled in 6 seconds) before and 
after bronchodilator administration.  In addition, severe asthmatics were less likely to perform 
well in pre- and post-bronchodilator measurements of FEF and PEF when compared with mild/ 
moderate asthmatics.  For the final lung function model, FEV1 percent predicted (OR = 1.09, CI 
=1.008 - 1.178), post-bronchodilator FVC (OR =1.984 , CI= 0.981 - 4.014 )  and pre- and post-
bronchodilator FEF (OR = 0.441 , CI =0.250 - 0.777  ; OR = 1.697, CI =0.975 - 2.817 ) were 
retained as risk factors for severe asthma.      
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Table 3.9.  Lung function-specific model for severe asthma.  Shown are the significant risk factors after univariate analysis and 
those that remained after multivariate analysis.  
 
 
  
Univariate analysis 
  
Multivariate analysis 
 
  
Odds ratio 
(Confidence interval) 
 
Global 
 p-value 
 
Lung function 
Model 
OR 
 
Lung function 
Model  
CI 
FEV1  percent predicted 1.090 ( 1.008 – 1.178) 0.0310 1.090 1.008 - 1.178 
FVC baseline 0.578 ( 0.423 – 0.789) 0.0002 ------- ------- 
Pre-bronchodilator FEF 0.393 ( 0.269 – 0.574) < 0.0001 ------- ------- 
Pre-bronchodilator PEF 0.702 ( 0.589 – 0.837) < 0.0001 0.441 0.250 - 0.777 
Post-bronchodilator FVC  0.654 ( 0.484 – 0.884) 0.004 1.984 0.981 - 4.014 
Post-bronchodilator FEF 0.418 ( 0.301 – 0.581) < 0.0001 -------- -------- 
Post-bronchodilator PEF 0.730 ( 0.612 – 0.871) 0.0002 1.657 0.975 - 2.817 
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Final severe asthma model. Risk factors from the 6 aforementioned sets that remained in their 
respective model after backward stepwise regression modeling ( n = 14) were grouped together 
for a final analysis.  The set of final predictor variables (n = 8) is shown in table 3.10 in 
descending order of statistical significance.   
 
 
Table 3.10. Final model for severe asthma.   Hosmer-Lemeshow goodness of fit χ2 = 12.06, p 
= 0.06.   
 
 
 
  
Severe asthma 
Model 
OR 
 
Severe asthma  
Model  
CI 
Seen a doctor in the last 12 months due to 
breathing problems 
5.904 1.829 - 19.056 
Use of additional controller medication (i.e. anti 
IgE, long acting β agonist, etc) 
4.593 1.524 - 13.846 
Nasal polyps 3.613 0.821 - 15.890 
ICU ever 3.507 0.921 - 13.361 
Gastroesophageal reflux disease (GERD) 3.245 1.196 - 8.805 
Provoking of asthma symptoms due to exercise  2.788 0.808 - 9.618 
Pneumonia 2.544 0.974 - 6.644 
FEV1  percent predicted 0.970 0.946 – 0.995 
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Post estimation tests. Shown in figure 3.1 are the results of the post-test estimations for model’s 
goodness of fit. With respect to the predictive variables in the final severe asthma model, the 
sensitivity (i.e.the probability of predicting severe asthma) was 72.7% and specificity ( i.e. the 
probability of predicting not severe asthma) was 93.3%.  Further validation of the final model is 
shown in Figure 1 which shows the area under the curve (AUC) of the receiving operating 
characteristic (ROC) = 0.91.  Using the Hosmer-Lemeshow goodness of fit test for the model, 
the resulting χ 2 = 12.06, p =0.06.  Therefore, the model is appropriate for the data.     
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Figure 3.1.    Post-test estimates. The predictable power of the final severe asthma model = 
92%.   The graph reflects this since the closer the curve follows the left-hand border and then 
the top border of the ROC space, the more accurate the test. The area under the curve (AUC) 
of the receiver operator characteristic (ROC)  is the measure discrimination (i.e. the ability of 
the test to correctly classify those with and without severe asthma).  
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3.3.6. Discussion 
 
The etiology of adult asthma is not fully understood.  One question that remains is why have 
measures of asthma morbidity have steadily increased over the past decade even though the 
asthma-specific mortality rate has steadily decreased (National Institutes of Health Asthma 
Education and Prevention Program, 2002).   These measures of morbidity include the need for 
continuous high-dose corticosteroids to control asthma symptoms and the frequent need for acute 
medical care due to these symptoms.   
 
       It is estimated that annual total direct health care expenditures for asthma care in the US is in 
excess of $11.3 billion (Weiss & Sullivan, 2001).  This estimate does not include indirect health 
costs such as lost work days. Of the $11.3 billion, approximately 60% is attributed to the costs of 
asthma medication.  It has been reported that although severe asthmatics comprise a small 
fraction of the total asthmatic population (i.e. 10%), they share a disproportionate burden of the 
total direct medical costs related to asthma spent every year in the US (S. Wenzel et al., 2005).   
A contributing factor to this expenditure is the lack of uniformity in asthma diagnosis, treatment, 
and severe asthma classification.    
 
       Individual characteristics such as female gender, and age have been identified as risk factors 
for severe asthma in the adult (Arruda et al., 2005; Kelley et al., 2005; King et al., 2004).  Other 
factors such as comorbidities  (i.e. sinusitis, bronchitis, GERD) and certain respiratory pathogens 
have recently garnered attention as additional risk factors for severe asthma (P. J. Cook et al., 
1998; Liou et al., 2003).  Some studies have shown an association with the frequency and 
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severity of asthma symptoms in the adult and infection caused by respiratory bacteria (Kraft, 
2000).  This is the different from what is observed in asthmatic children who tend to be more 
susceptible to respiratory viruses (Lemanske, 2003).   The increased interest in risk factors for 
severe adult asthma is supported by the observation that adult-onset asthmatics tend to have a 
greater and more rapid decline in lung function that is not reflective of disease duration (Miranda 
et al., 2004).  Thus, it is believed that adult-onset asthma, specifically adult severe asthma, may 
be a disorder distinct from childhood-onset asthma.   
 
Atypical respiratory bacteria is a term used to distinguish a group of bacteria (ie. Chlamydia, 
Mycoplasma, Legionella) from those such as streptococcus that are “typically” recognized as 
being responsible for respiratory infections (Hammerschlag, 2000, 2001).   One research 
question is how these pathogens are able to influence the prevalence and frequency of asthma 
symptoms.  It is suggested that components of the bacteria, such as chaperone proteins, may 
evoke a persistent antigenic response in asthmatics (Bertorelli et al., 1998; Betsou et al., 2003; 
Costa et al., 2002; Huittinen et al., 2001).  This could explain the presence of pro-inflammatory 
cytokines and persistent elevated levels of IgE in the absence of atopy in these patients.   
 
       The relationship between asthma symptoms and atypical pathogens has been strictly 
associative.  A published study in 1995 showed that within a pediatric study population,  
persistent infection with Chlamydia pneumonia (Cpn) resulted in chronic immune activation 
(Emre et al., 1995).  In a study by Nagy, et al, it was found that those who had a variation in the 
gene that encodes for a defense protein that acts against microbes were at higher risk for asthma 
(Nagy et al., 2003).   A group headed by ten Brinke in the Netherlands showed that adults with 
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non-atopic asthma and positive Cpn IgG experienced persistent airflow limitation when 
compared with their matched controls (ten Brinke et al., 2001). The most recent study to address 
this relationship in adults was conducted at National Jewish Hospital in Denver, CO. Drs. 
Richard Martin and Monica Kraft observed elevated amounts of Cpn-specific m-RNA and Cpn-
specific antibodies in the bronchial cells of their study population (Kraft, 2000; Kraft et al., 
2001; Martin et al., 2001).  They interpreted their findings to indicate that Cpn antigens can 
evoke an IgE mediated response.   However, authors concur that the further investigation of the 
relationship between infections caused by atypical respiratory pathogens and adult asthma 
severity needs to be tested in a larger samples fo asthmatics stratified by disease severity.    
 
       This study tested the hypothesis that infections caused by the atypical pathogens, 
Mycoplasma pneumonia (Mpn) and Chlamydia pneumonia (Cpn) are risk factors for severe 
asthma.  The study population (n = 233), which was enrolled in the Severe Asthma Research 
Project (SARP), ranged in age was age 15-68 years and was stratified into three groups: normal 
controls, mild/moderate asthmatics, and severe asthmatics.  The gender distribution across all 3 
groups was a fair representation of the gender distribution in adult asthma (ENFUMOSA, 2003).  
In addition, the personal characteristics of the group reflected previous studies that have shown 
severe asthmatics tend to be older and have a higher BMI (Akerman et al., 2004; Varraso et al., 
2005).   
 
       To determine infection by Mpn or Cpn, peripheral serum samples were evaluated for the 
presence of antibodies specific to these pathogens.  Distribution analysis revealed a higher 
prevalence of Mpn infection in the mild/moderate asthmatics (data not shown).  This translated 
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into a lower risk conferred by Mpn infection  for severe asthmatics that was statistically 
significant (OR =0.518 CI = 0.289 - 0.928).  Conversely, although severe asthmatics had a 
slightly higher prevalence of Cpn infection, it was not statistically significant.  One explanation 
could be the fact that most of the severe asthmatics regularly use high-dose anti-inflammatory 
drugs to control their asthma.  In addition, treatment with antibiotics for bronchitis and sinusitis 
was significantly higher in the severe asthma group when compared to the mild/ moderate group.    
These 2 factors may account for the finding of an elevated risk of infection in the mild/moderate 
group.  
 
       In addition to testing the aforementioned hypothesis, we were able to assess other factors 
contributing to the severe asthma phenotype.   With respect to disease severity, statistically 
significant risk factors that were identified in these models included current diagnosis of 
gastroesophageal reflux disease (GERD) and current use of hormone replacement therapy 
(HRT).   In the Nurses Health Study Higher, a higher prevalence of HRT was reported in women 
who developed asthma as an adult (R. Graham Barr, 2004; R. G. Barr & Camargo, 2004). It has 
also been previously reported that GERD and obesity are associated with nocturnal asthma 
symptoms (Gunnbjornsdottir et al., 2004) We interpret the finding of GERD and HRT as 
statistically significant risk factors for severe asthma as a biologically plausible mechanism 
regarding the higher prevalence of severe asthma in females.  
 
       The role that allergy and inflammation have in the pathophysiology of severe asthma is not 
clear.  In our cohort, severe asthmatics in our cohort had lower measures of allergic sensitization 
via the allergy skin test and lower measures of peripheral serum inflammatory biomarkers (i.e 
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IgE, eosinophils).  However, the risk conferred from self-reported seasonal allergy symptoms 
and the percentage of serum neutrophils was statistically significant.   Finally, other studies have 
noted an increased percentage of neutrophils in severe asthmatics hypothesizing that this is due 
to the pharmacological nature of high-dose inhaled corticosteroids (Jatakanon et al., 1999; Little 
et al., 2002; S. E. Wenzel et al., 1997).  However, since neutrophils are part of the innate immune 
response to pathogens, the role of respiratory infection in this phenomenon should be further 
explored.   
 
       This is the largest published study to date that has investigated the relationship of atypical 
respiratory infection and the patho-physiology of severe adult asthma.   Although we were 
limited to testing this hypothesis in the peripheral serum of study subjects, further investigation 
of this hypothesis should include bronchial specimens obtained from the SARP study 
participants.  
 
       The opportunity created by this NIH-funded study will allow investigators to address the 
uncertainties regarding the risk factors for severe adult asthma.  Thorough understanding of this 
complex disease will have long-reaching public health effects through appropriate clinical 
intervention and management of relevant exposures and risk factors.   
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4. DISCUSSION 
 
4.1.Overview 
 
For the past decade, evidence supporting the disproportionate distribution of environmentally-
related disease amongst the US population has increased (Gold & Wright, 2005; Olden & White, 
2005).   Healthy People 2010, the US Department of Health and Human Service’s program for 
addressing health disparities has prioritized the reduction of exposures that contribute to the 
etiology of environmentally-related disease (U.S. Department of Health and Human Services, 
2000).  However, surveillance for environmentally related disease does not exist.  Asthma is one 
such disease. 
 
       Currently, the Centers for Disease Control’s (CDC) Behavioral Risk Factor Surveillance 
System (BRFSS) is the most frequently utilized tool to estimate baseline prevalence of chronic 
disease in the US (Centers for Disease Control, 2005a).  This random-number telephone survey 
samples populations periodically for incidence and prevalence of disease.  Changes in such 
prevalence over time are often published by the CDC in their Morbidity and Mortality Weekly 
Report (MMWR) (Centers for Disease Control, 2005b).  However, since these estimates are at 
the national level, the CDC encourages local adaptation of the BRFSS. State and local agencies 
have adopted the BRFSS to address local public health issues but the BRFSS is rarely used by to 
estimate the local prevalence and morbidity of chronic disease. 
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       Recently, the CDC has established the Environmental Public Health Indicator (EPHI) 
project(C. f. D. C. National Center for Environmental Health, 2005). The long-term goal is to 
incorporate the local surveillance of the prevalence and morbidity of non-infectious chronic 
diseases into a national public health surveillance system by identifying indicators of 
environmental health.  
 
       One index of chronic disease prevalence and morbidity that has been cited in the CDC’s 
MMWR is hospital discharge statistics (C. f. D. C. National Center for Health Statsitics, 2005).  
The National Center for Health Statistics at the CDC regularly collects these data via a sample 
survey of hospitals in the US.  As a health effects indicator, the CDC has recognizes the utility of 
hospitalization data as a source to detect unusual patterns of events specific to environmentally-
related disease.   One such disease is asthma.  
 
       Asthma is a chronic respiratory disease whose etiology is suspected of being 
environmentally-related (Allacci, 2005; S. Holgate, 2001; S. T. Holgate, 1999).  In the past 
decade as the incidence of newly diagnosed asthma has remained stable,  the prevalence of   
persistent asthma symptoms has increased (Lawson & Senthilselvan, 2005).  One question that 
remains is why  these measures of asthma morbidity have steadily increased (National Institutes 
of Health Asthma Education and Prevention Program, 2002).   Measures of morbidity also 
include health care utilization. It is estimated that annual total direct health care expenditures for 
asthma care in the US is in excess of $11.3 billion (Weiss & Sullivan, 2001).  Of the $11.3 
billion, approximately 60% is attributed to the costs of asthma medication.  Traditionally 
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regarded as a childhood disorder, in recent years asthma has emerged as a public health concern 
of adults age 19-64 (Dolan et al., 2004).  
       Adult- or late-onset asthma has been added to the current phenotypes of asthma (Bel, 2004). 
Although many studies have published that address the risk factors for child-onset asthma, the 
risk factors for adult-onset asthma remain poorly defined.  Without surveillance or a standardized 
protocol for diagnosis, the prevalence of adult asthma and adult asthma morbidity morbidity is 
believed to be greatly underestimated (W. Busse et al., 2004; National Institutes of Health 
Asthma Education and Prevention Program, 2002).    
 
       It has been reported that individuals with one phenotype of asthma, severe asthma, comprise 
a small fraction of the total asthmatic population (i.e. 10%).  As the name implies, severe or 
difficult-to-treat asthma, has grater difficult managing their disease (S. Wenzel et al., 2005).  In 
addition, this subpopulation of asthmatics shares a disproportionate burden of the total direct 
medical costs related to asthma spent every year in the US.   A contributing factor to this 
expenditure is the lack of uniformity in asthma diagnosis, treatment, and severe asthma 
classification.    
 
       Risk factors for severe asthma in the adult include female gender, race, and age (Arruda et 
al., 2005; Kelley et al., 2005; King et al., 2004).  It is unclear if age as a risk factor is due to the 
age at disease onset or the duration of disease in an individual (Burrows, Barbee, Cline, 
Knudson, & Lebowitz, 1991; Busse, Banks-Schlegal, & Wenzel, 2000; Lange, Parner, Vestbo, 
Schnohr, & Jensen, 1998; Peat, Woolcock, & Cullen, 1987).  Additional risk factors for severe 
asthma include comorbidities  such as sinusitis, bronchitis, and GERD. (P. J. Cook et al., 1998; 
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Liou et al., 2003).  Infection with certain respiratory pathogens have also been identified for risk 
factors ((P. J. Cook et al., 1998; Liou et al., 2003).  The need for understanding risk factors for 
severe adult asthma is supported by the fact that adult-onset asthmatics tends to have a greater 
and more rapid decline in lung function that is not reflective of disease duration (Miranda et al., 
2004).  Thus, it is believed that adult-onset asthma, specifically adult severe asthma, may be a 
distinct disorder from childhood-onset asthma.   Therefore, the public health significance of 
delineating risk factors for adult asthma morbidity is greater than ever.   
 
       Environmental epidemiology uses interdisciplinary approaches to address suspect risk 
factors of health outcomes related to the environment.  These can range from molecular and 
cellular biology for assessing the prevalence of biomarkers to environmental engineering to 
assess the spatial distribution of exposures and health outcomes (Boffetta, 2002; Briggs, 2005; 
Kunzli, 2005).  Environmental engineering has also contributed the concept of “source 
apportionment”; the identification of the source of elements in air pollution (i.e. industry, 
commercial vehicles, agriculture). The advent of electronic medical records is increasingly a data 
source for the development of local disease morbidity. The expansion of biostatistical methods 
with respect to predicting health outcomes, including the assessment of a range of risk factors 
while controlling for numerous confounding variables, has furthered the development of 
environmental epidemiology.  Here we summarize the use of these novel approaches to assess 
the prevalence of environmental risk factors for adult asthmatics.  
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4.2. Summary of results 
 
4.2.1. Using mapping technology and Poisson statistics to assess adult asthma hospitalization 
rates within the urban-rural context.  
Epidemiological studies have suggested that a rural environment confers protection against the 
development of childhood asthma (von Mutius, 2001).  More recent reports from China and 
Europe have indicated a reduction in the prevalence of childhood asthma in rural settings (Chan-
Yeung et al., 2002; Waser et al., 2005).  This “hygiene hypothesis” suggests that exposures from 
farming and livestock tend to protect children from the development of asthma.  In our first 
study, we did not observe a protective effect of a farming environment for adult asthmatics.  
Lancaster County and Erie County both have substantial agricultural industry, yet their adult 
asthma hospitalization rates were substantially different.  
 
       Abundant roads and highways to accommodate heavy traffic often characterize an urban 
community.  Most studies that address the relationship of this urban characteristic with the 
frequency and severity of asthma symptoms have focused on children (Nicolai et al., 2003).  For 
example, (Kim et al., 2004) the proximity of roads to schools, and their relationship with asthma 
symptoms.  The authors found spatial variability in traffic related pollutants and an influence of 
this variability on the frequency of asthma symptoms in children.  
 
       Previous studies have shown that emissions from commercial traffic is more detrimental 
than car emissions with respect to respiratory symptoms (Janssen et al., 2003; van Vliet et al., 
1997).  Geographical areas with low SES have been reported to have a higher prevalence of  
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commercial trucking routes  (Brown et al., 2003; Lwebuga-Mukasa et al., 2004).  This may 
explain why Fayette County, an area characterized as least urban, but with low SES, had the 
highest adult asthma hospitalization rate.   
 
       Increased asthma morbidity in adult females has been reported (NAEPP, 2002).  We found 
asthma hospitalization rates in all 6 counties were higher for females than for males.  This is 
reflective of the National Institutes of Health’s report that 61% of adult asthmatics are female. A 
recent European study found that females, regardless of their geographic location, had higher 
indices of chronic disease severity than males (ENFUMOSA, 2003).  Biological mechanisms, 
such the endocrine shift during the menstrual cycle, or menopause, have been suggested to be 
responsible for this gender disparity (Haggerty, Ness, Kelsey, & Waterer, 2003; Vrieze, Postma, 
& Kerstjens, 2003).  It has also been hypothesized that the health seeking behavior of women, 
when compared with men, may explain gender disparities in chronic disease (McCance-Katz, 
Carroll, & Rounsaville, 1999; Meyer-Weitz, Reddy, Van den Borne, Kok, & Pietersen, 2000).  
Further cohort studies are needed to gain a better understanding of the gender disparity in adult 
asthma hospitalization rates.  
 
4.2.2. Using local asthma hospitalization data and mapping technology to assess the local 
burden of asthma morbidity.  
Here we report the utilization of local adult asthma hospitalization data as an environmental 
health indicator in Allegheny County., Pennsylvania which includes the city of Pittsburgh.   
 
       The total adult asthma hospitalization rate for Allegheny County was comparable to the 
CDC’s latest estimates (National Center for Health Statistics, 2005).  Comparable profiles were 
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observed for both gender-specific and age specific rates.  However, the race-specific rates for 
African –Americans were slightly elevated.  This suggests the possibility of a greater burden of 
adult asthma hospitalizations in Blacks.   
 
       Most studies investigating the temporal distribution of asthma events have focused on the 
daily ambient air quality (Galan et al., 2003; Neidell, 2004; Wilson et al., 2005).  Air quality in 
the US is based on the concentrations of criteria air pollutants as defined by the Environmental 
Protection Agency (EPA) (United States Environmental Protection Agency, 2005).  They include 
sulfur dioxide (SO2), nitrogen dioxide (NO2), carbon monoxide (CO), ozone (O3), and particulate 
matter <10um (PM10) and <2.5um (PM2.5).  The EPA’s daily Air Quality Index (AQI) is 
reflective of the concentrations of the main pollutant on the day of interest; the higher the index, 
the poorer the air quality.  With respect to health effects, the most investigated pollutant is ozone.  
Published studies have shown the adverse effects of ozone even in healthy individuals 
(McConnell et al., 2002; Mudway & Kelly, 2004).   
 
       Our study showed that on days of increased adult asthma hospitalizations, the air quality 
index was lower (i.e. better air quality).  In addition, the main pollutant on these days was not 
ozone but particulate matter.  Further assessment of the relationship of the daily main pollutant 
and hospitalization frequencies demonstrated identified a positive correlation of PM10 and an 
inverse correlation of ozone.  Numerous studies have cited a relationship between respiratory and 
cardiopulmonary hospitalizations on or about days where PM is the main pollutant (Delfino et 
al., 2005; Kappos et al., 2004; Ruidavets et al., 2005; Thurston & Bates, 2003).  An explanation 
may be that the degree of obstruction due to tissue remodeling is greater in the adult (Bai & 
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Knight, 2005; S. Wenzel et al., 2005).   Another explanation may be that the influence of 
seasonal bacterial respiratory infections on adult asthma morbidity is greater than previously 
thought.   
   
       The impact that the environment has on health effects and disease prevalence is frequently 
cited within the context of environmental justice.  One tenet of environmental justice is that 
individuals must have control over exposures in their environment (Apelberg et al., 2005; Brulle 
& Pellow, 2005; Gee & Payne-Sturges, 2004).  Since our dataset included the patient’s zip code 
of residence, we assessed the influence of zip-code specific characteristics such as poverty and 
the prevalence of industrial facilities on the respective rates.  We found an elevated risk of adult 
asthma hospitalization associated with factors of SES such as poverty and lower educational 
attainment.  The 14 zip codes with higher rates, located predominantly in the Southeastern 
quadrant of the county, also had higher percentage of African-Americans residents.   In addition, 
indices of exposure to industrial sites were not statistically significant.   However, since the exact 
address of patients in this study were not available, further quantification of exposure effects was 
not possible 
 
4.2.3 Integrating laboratory methods into environmental epidemiology 
Our third study tested the hypothesis that infections caused by the atypical pathogens, 
Mycoplasma pneumonia (Mpn) and Chlamydia pneumonia (Cpn) are risk factors for severe 
asthma.  The rationale for this hypothesis was the aforementioned observation that adult 
asthmatics have a higher frequency of hospitalization during the winter.  These bacteria belong 
to a class known as atypical respiratory pathogens. The term “atypical” bacteria is used to 
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distinguish a group of bacteria (ie. Chlamydia, Mycoplasma, Legionella) from those such as 
streptococcus that are “typically” recognized as being responsible for respiratory infections 
(Hammerschlag, 2000, 2001).    
 
       The relationship between asthma symptoms and atypical pathogens has been strictly 
associative.  Emre, et al observed in their pediatric population that persistent infection with 
Chlamydia pneumonia (Cpn) resulted in chronic immune activation (Emre et al., 1995).  In a 
study by Nagy, et al, it was found that those who had a variation in the gene that encodes for a 
defense protein that acts against microbes were at higher risk for asthma (Nagy et al., 2003).   A 
group headed by ten Brinke in the Netherlands showed that adults with non-atopic asthma and 
positive Cpn IgG experienced persistent airflow limitation when compared to their matched 
controls (ten Brinke et al., 2001). The most recent study to address this relationship in adults was 
at National Jewish Hospital in Denver, CO. Drs. Richard Martin and Monica Kraft observed 
elevated amounts of Cpn-specific m-RNA and Cpn-specific antibodies in the bronchial cells of 
their study population (Kraft, 2000; Kraft et al., 2001; Martin et al., 2001).  They interpreted 
their findings that with respect to the Cpn-specific IgE, antigens of Cpn can evoke an IgE 
mediated response.   However, a common theme across all of the studies is that the contribution 
of atypical pathogens to asthma severity needs to be tested in a larger sample of asthmatics 
stratified by disease severity.    
 
       Our study population (n = 233), which was enrolled in the Severe Asthma Research Project 
(SARP), ranged in age was age 15-68 years and was stratified into three groups: normal controls, 
mild/moderate asthmatics, and severe asthmatics.   The gender distribution across all 3 groups 
was a fair representation of the gender distribution in adult asthma (ENFUMOSA, 2003).  In 
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addition, the personal characteristics of the group reflected previous studies which have shown 
that severe asthmatics tend to be older and have a higher BMI (Akerman et al., 2004; Varraso et 
al., 2005).   
 
       To determine infection by Mpn or Cpn, peripheral serum samples were evaluated for the 
presence of antibodies specific to these pathogens.  Distribution analysis revealed a higher 
prevalence of Mpn infection in the mild/moderate asthmatics (data not shown).  This translated 
into a lower risk conferred by Mpn infection  for severe asthmatics that was statistically 
significant (OR =0.518 CI = 0.289 - 0.928).  In comparison, severe asthmatics had a slightly 
higher prevalence of Cpn infection, it was not statistically significant.  One explanation could be 
the fact that the all of the severe asthmatics are currently using high-dose anti-inflammatory 
drugs to control their asthma.  In addition, the use additional anti-inflammatory asthma 
medications and treatment with antibiotics for bronchitis and sinusitis was significantly higher in 
the severe asthma group when compared to the mild/ moderate group.    Finally, it has been cited 
that individuals with severe chronic disease are more likely to take preventive measures that 
would have a negative impact on their health.  Thus, severe asthmatics may take extra measures 
to care to reduce environmental exposures that would precipitate an exacerbation.   
 
       In addition to testing the aforementioned hypothesis, we were able to assess additional 
information gathered from the study participants.  Various predictive models with respect to 
disease severity were generated using backward stepwise regression analysis.  Statistically 
significant risk factors that were identified in these models included current diagnosis of 
gastroesophageal reflux disease (GERD) and current use of hormone replacement therapy 
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(HRT).   Higher prevalence of HRT use in women enrolled in the Nurses Health Study who 
developed asthma as an adult was reported last year (R. Graham Barr, 2004; R. G. Barr & 
Camargo, 2004). It has also been previously reported that GERD and obesity is associated with 
nocturnal asthma symptoms (Gunnbjornsdottir et al., 2004) We interpret the finding of GERD 
and HRT as statistically significant risk factors for severe asthma as a biologically plausible 
mechanism regarding the higher prevalence of severe asthma in females.  
 
       The role that allergy and inflammation plays in the pathology of severe asthma is also not 
quite understood.   Severe asthmatics in our cohort had lower measures of allergic sensitization 
via the allergy skin test and lower measures of peripheral serum inflammatory biomarkers ( i.e 
IgE, eosinophils).  However, the risk conferred from seasonal allergy symptoms and the 
percentage of serum neutrophils was statistically significant.   Self-reported frequency and 
severity of seasonal allergy symptoms by the severe asthma group was higher during the fall and 
winter.    Thus, one could infer that exacerbations due to seasonal environmental exposures such 
as particulate matter and cold weather could be interpreted as allergies.   Finally, other studies 
investigating the increased percentage of neutrophils observed in severe asthmatics hypothesize 
that this observation is due to the pharmacological nature of high-dose inhaled corticosteroids 
(Jatakanon et al., 1999; Little et al., 2002; S. E. Wenzel et al., 1997).  However, since 
neutrophils are part of the innate immune response to foreign agents, such as pathogens, the role 
that respiratory infection plays in this phenomenon should be further explored.   
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       Our final model for severe asthma identified GERD and having nasal polyps with higher 
odds ratios for predicting severe asthma.  These were also stronger predictive factors that 
pneumonia and frequent need for medical care due to asthma.    
 
4.3. The public health significance and future directions 
These studies represent 3 projects that had yet to be addressed in local asthma research.  The 
urban-rural study was first such study to address measures of urbanization and the influence of 
urbanization on adult asthma hospitalization rates.  The Commonwealth contains areas with high 
population density and others with low population density.  It also has a stable population that 
tends to relocate infrequently.  This stability is important when assessing the change over time in 
hospitalization frequency.  The unexpected trend of increased hospitalization with decreasing 
size of the populace and decreased urbanization suggests a strong influence of demographic and 
socioeconomic factors.  These factors should be further explored to better understand their 
influence on human respiratory health.  
 
       In our second study, we showed that hospitalization data that includes all health care 
facilities are a useful tool for estimating disease morbidity within a community.  The 
Commonwealth of Pennsylvania is only one of three states within the US that collects such data.  
The timeliness and availability of the data adds to its utility of being used in the capacity of an 
environmental health indicator.  In addition, this is the first study to estimate the burden of 
asthma morbidity within Allegheny County, PA using the criteria set forth by the CDC for 
environmental health surveillance.  By developing this environmental health capacity, 
meaningful and appropriate public health interventions can be implemented.   
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       The third study is the largest published study to date that has investigated the relationship of 
atypical respiratory infection and the patho-physiology of severe asthma in adults.   Although we 
were limited to testing this hypothesis in the serum, future directions include further 
investigation of this hypothesis using bronchial specimens obtained from the SARP study 
participants.   The opportunity created by this NIH-funded study will allow investigators to 
address the uncertainties regarding the risk factors.  Thorough understanding of this complex 
disease will have long-reaching public health effects through appropriate clinical intervention 
and management of relevant environmental exposures and risk factors.   
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APPENDIX A  
Distribution Tables and Results of Univariate Analysis from Chapter 3 
 
Factors assessed for risk of disease severity 
 
Category of factor Examples 
 Personal characteristics Age, gender , BMI 
 Biomarkers of respiratory infection Mycoplasma pneumonia and Chlamydia pneumonia  seropositivity,  Mycoplasma 
pneumonia and Chlamydia pneumonia  infection classification (ie current, past, 
chronic)  
 Allergy  (atopy) history Age of onset, causes breathing problems, seasonal symptom frequency, atopy 
score 
 Allergy skin test Mold, vegetation, cat, dog, allergen positivity score 
 Asthma history Yrs with asthma, age of onset 
 Asthma quality of life measurements Scores for symptoms, activity, emotions, environment and overall 
 Asthma symptoms Frequency of cough, sputum, chest tightness, wheeze, shortness of breath, 
nocturnal breathing difficulty, use of rescue inhaler; duration of asthma attacks 
 Blood analysis White blood cell differentials, Hemoglobin, Hematocrit 
 Family history Asthma, allergies, eczema (father, mother, sibling, child) 
 For women only Pre-menstrual symptoms, ovarian or uterine surgery 
 Lung function test (Spirometry) Measurements of obstructive lung disorder (FEV, FVC, PEF, FEF) 
 Medical care utilization Doctor office visits, ED or hospitalization, ICU 
 Medication use In general, patterns of ICS and B-agonist use 
 Non-respiratory co-morbidities GERD, osteoporosis, diabetes 
 Pet ownership Cat, dog, rodent, bird 
 Provoking factors Animal, activity, exercise, aspirin 
 Respiratory co-morbidities Pneumonia, acute and chronic bronchitis, sinusitis, sinus surgery, nasal polyps,  
polyp surgery 
 Tobacco use and exposure Smoking status, including length and beginning age; exposure to environmental 
tobacco smoke  
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Personal characteristics  
1.    Distribution  
 
  
 
Normal 
N = 18  
 
Mild/moderate asthma 
N = 152  
 
Severe asthma 
N = 63  
Gender                  # ( %)    
      Male                     7  (39)  43 (28.3) 23 (36.5) 
      Female                 11 ( 61) 109 (71.7) 40 (63.5) 
Age                        # ( %)    
     All          median 
(range) 
25.9 (18.9 – 49.0) 30.8 (13.0 – 63.2)  44.1 ( 16.7 – 68.1) 
             By gender    
                       Male 25.9 ( 22.5 – 42.4) 28.4 (13.2 – 57.7 ) 44.9 (22.1 – 66.5) 
                       Female 24.3 (18.9 – 48.0) 32.9 (13.0 – 63.2) 43.8 (16.7 – 68.1) 
BMI                      # ( %)      
All          median (range) 26.7 ( 20.6 – 47.6) 28.0 ( 17.4 – 63.9)  30.0 (19.8 – 55.7) 
             By gender    
                       Male 26.4 ( 23.9 – 47.6) 26.4 (17.4 – 41.2) 28.7 (20.1 – 45.0) 
                       Female 27.0 ( 20.6 – 37.6) 28.2 (17.8 – 63.9)  31.3 (19.8 – 55.7) 
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  2. Univariate analysis personal characteristics.       
        
 
 Odds ratio (CI) Global p value 
Gender 0.686   (0.368 - 1.279) 0.238 
Age 
    
1.070   (1.041  - 1.010) 
 
<0.001 
 
BMI 
     
1.028  (0.992  - 1.065) 
 
0.134 
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Biomarkers of respiratory infection specific from Mycoplasma pneumonia (Mpn) and Chlamydia pneumonia  (Cpn) 
 
1.  Distribution  
  
Normal 
N = 18  
 
 
Mild/moderate asthma 
N = 152  
 
 
Severe asthma 
N = 63 
 
Asthma provoked by respiratory infection        #  ( %) 0 134  ( 91) 60  (95) 
Mycoplasma pneumonia +   subjects                 # ( %)   9  ( 56.2)   89 ( 61.8) 31 ( 45.6) 
By degree of infection    
Current 1  ( 5.6) 3  ( 2.0) 3 ( 4.8) 
Past 5 ( 27.8) 49 ( 32.5) 19 ( 30.2) 
Chronic 0 9  ( 5.9) 0 
Borderline 2 ( 11.1) 18 ( 11.8) 9 ( 14.3) 
Current / past 2 ( 11.1) 11  ( 7.2) 0 
Past / chronic 1  ( 5.6) 8  ( 5.3) 3 ( 4.8) 
Current / past / chronic 0 4  ( 2.6) 2 ( 3.2) 
Chlamydia pneumonia +     subjects                  # ( %)   10 ( 62.5) 72 ( 50) 36 ( 52.9) 
By degree of infection    
Current 1  ( 5.6) 1    ( 0.7) 1 ( 1.6) 
Past 4 ( 22.2) 26 ( 17.1) 14 ( 22.2) 
Chronic 1  ( 5.6) 10  ( 6.6) 0 
Borderline 0 0 1 ( 1.6) 
Current / past 0 3   ( 2.0) 0 
Past / chronic 5 ( 27.8) 33  ( 21.7) 18 ( 28.6) 
Current / past / chronic 1  ( 5.6) 4   ( 2.6) 0 
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2.  Univariate analysis 
 
 
Factor Odds ratio (CI) Global p value 
Asthma provoked by respiratory infection            2.090 (0.579  -  7.542) 0.230 
Mpn + 0.518  (0.289  -  0.928) 0.027 
Cpn + 1.140  (0.674  - 1.928)  0.625 
Mpn+ by category 
Current
Past
Chronic
Borderline
Current / past
Past / chronic
Current / past / chronic
 
 
 
2.162 ( 0.426 – 10.968) 
0.728 9 0.397 – 1.334) 
0.408 ( 0.087 – 1.909) 
1.003 ( 0.431 – 2.333) 
0.182 ( 0.023 – 1.434) 
0.785 ( 0.202 – 3.046) 
1.060 ( 0.190 – 5.916) 
 
0.352 
0.300 
0.215 
0.994 
0.106 
0.727 
0.947 
 
Cpn+ by category 
Current
Past
Chronic
Borderline
Current / past
Past / chronic
Current / past / chronic
 
 
2.000 ( 0.123 – 32.377) 
1.391 ( 0.727 – 2.663) 
0.189 ( 0.024 – 1.503) 
-------- 
-------- 
1.325 ( 0.725 – 2.421) 
------- 
 
0.629 
0.323 
0.115 
------- 
------- 
0.363 
------- 
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Allergy (atopy) history  
 
1. Distribution 
 
 
                                                       
                                                      
 
Normal 
N = 18 
 
Mild/moderate asthma 
N = 152 
 
Severe asthma 
N = 62 
Allergy symptoms w/o cold or flu             
                                                       # (%) 
 
3 (16.6) 
 
146 (96) 
 
58 (93.6) 
Age allergy onset                                       
                                       median (range) 
 
3 ( 0 – 41) 
 
9  ( 1 – 53) 
 
11  ( 0  - 48) 
Still symptomatic                                       
                                                      #  (%) 
 
2 (25) 
 
140 (97) 
 
56 (98.3) 
Allergies make you breath worse              
                                                      #  (%) 
 
0 
 
130 (90.9) 
 
58 (98.3) 
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2. Distribution of seasonal frequency of allergy symptoms 
 
  
Normal 
N=18 
 
 
Mild/moderate asthma 
N = 152 
 
 
Severe asthma 
N = 62 
Spring allergies                                    
                                                 #  (%) 
 
 
  
     None
     Mild
     Moderate
     Severe
15 ( 83.3) 
2 ( 11.1) 
1 ( 5.6) 
0 
9 ( 6.0) 
45 ( 29.6) 
60 ( 39.5) 
38 ( 25.0) 
13 ( 4.8) 
12 ( 19.3) 
27 ( 43.5) 
20 ( 32.3) 
Summer allergies                                  
                                                 #  (%) 
   
     None
     Mild
     Moderate
     Severe
15 ( 83.3) 
2 ( 11.1) 
1 ( 5.6) 
0 
19 ( 12.5) 
63 ( 41.5) 
55 ( 36.2) 
15 ( 9.9) 
8 ( 12.9) 
19 ( 30.7) 
22 ( 35.5) 
13 ( 21.0) 
Fall allergies                                         
                                                 #  (%) 
   
     None
     Mild
     Moderate
     Severe
15 (83.3_ 
3 ( 16.7) 
0 
0 
13 ( 8.6) 
45 ( 29.6) 
67 ( 44.1) 
27 ( 17.8) 
5 ( 8.1) 
14 ( 22.6) 
23 ( 37.1) 
20 ( 32.3) 
Winter allergies                                    
                                                 #  (%) 
   
     None
     Mild
     Moderate
     Severe
17 ( 94.4) 
1 ( 5.6) 
0 
0 
37 ( 24.3) 
60 ( 39.5) 
36 ( 23.7) 
19 ( 12.5) 
10 ( 16.1) 
20 ( 32.3) 
16 ( 25.8) 
16 ( 25.8) 
Total seasonal atopy score                   
                                   median (range)
 
4 ( 4 – 9) 
 
10  ( 4 – 16) 
 
11.5 ( 4 – 16) 
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3. Univariate analysis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Odds ratio (CI) Global p value 
Allergy symptoms w/o cold or flu              0.596 ( 0.162 – 2.189) 0.444 
Age allergy onset                     1.032 ( 1.005 – 1.061) 0.021 
Still symptomatic                                       2.0 ( 0.228 – 17.504) 0.502 
Allergies make you breath worse             5.8 ( 0.741 – 45.386) 0.064 
Spring allergies                                            
                     Mild
                     Moderate
                     Severe
0.0571 ( 0.278 – 1.172) 
1.183 ( 0.650 – 2.151) 
1.429 ( 0.748 – 2.728) 
0.116 
0.583 
0.284 
Summer allergies                                        
Mild
                     Moderate
                     Severe
0.624 ( 0.333 – 1.171) 
0.970 ( 0.524 – 1.797) 
2.423 ( 1.077 – 5.453) 
0.137 
0.923 
0.035 
Fall allergies                                                
Mild
                     Moderate
                     Severe
0.693 ( 0.348 – 1.382) 
0.748 ( 0.408 – 1.372) 
2.205 ( 1.122 – 4.333) 
0.291 
0.346 
0.023 
Winter allergies                                           
     Mild
                     Moderate
                     Severe
0.730 ( 0.391 – 1.363) 
1.121 ( 0.567 – 2.214) 
2.435 ( 1.156 – 5.127) 
0.319 
0.744 
0.021 
Total seasonal atopy score               1.151 ( 1.026 – 1.291) 0.014 
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Allergy Skin Test 
 
1.  Allergens applied during the skin test 
 
Histamine 1 mg/ml (+ control) 
50% glycerin in 50% saline (- control) 
Dermatophagoides pteronyssinus 
Cat 
Dog 
American cockroach 
Alternaria 
Cladosporium 
Aspergillus mix 
Timothy grass (or grass mix) 
Short ragweed 
Common weed mix: cocklebur, lambs quarter, pigweed, English plantain, Russian thistle 
Eastern 7-tree mix: white ash, American beech, red birch, American elm, shagbark hickory, red oak, cottonwood 
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2.  Distribution  
 
Allergen  
Normal 
N = 18 
 
 
Mild/ moderate asthma 
N = 149 
 
Severe asthma 
N = 57 
Alternaria                                # positive ( %) 0 47 ( 31.5) 14 ( 24.6) 
Aspergillus  0 15 ( 10.1) 5 ( 8.8) 
Cat 2 ( 11.1) 69 ( 46.3) 23 ( 40.4) 
Cladosporium 0 9 ( 6.0) 5 ( 8.8) 
Cockroach 0 48 ( 32.2) 10 ( 17.5) 
D. farinae 2 (11.1) 101 ( 67.8) 29 ( 50.9) 
D. pteronyssinus 3 ( 16.7) 103 ( 69.1) 34 ( 59.7) 
Dog 0 37 ( 24.8) 6 ( 10.5) 
Grass mix 0 68 ( 45.6) 18 ( 31.6) 
Ragweed 0 73 ( 49.3) 20 ( 36.4) 
Tree mix 
 
0 46 ( 30.1) 12 ( 21.1) 
Weed mix 0 55 ( 36.9) 9 ( 15.8) 
Total allergy score                median ( range) 0 ( 0 – 3) 4 ( 0 – 12) 3 ( 0 – 12) 
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3. Univariate analysis  
 
 Odds ratio (CI) Global p-value 
Alternaria 0.706 ( 0.353 – 1.416) 0.321 
Aspergillus  0.859 ( 0.297 – 2.483) 0.777 
Cat 0.784 ( 0.422 – 1.457) 0.441 
Cladosporium 1.496 ( 0.479 – 4.670) 0.496 
Cockroach 0.448 ( 0.208 – 0.961) 0.031 
D. farinae 0.492 ( 0.264 – 0.917) 0.026 
D. pteronyssinus 0.660 ( 0.350 – 1.243) 0.201 
Dog 0.356 ( 0.141 – 0.897) 0.017 
Grass mix 0.550 ( 0.288 – 1.048) 0.064 
Ragweed 0.587 ( 0.310 – 1.110) 0.098 
Tree mix 0.597 ( 0.289 – 1.233) 0.153 
Weed mix 0.320 ( 0.156 – 0.703) 0.002 
Total allergy score                     0.848 ( 0.751 – 0.957) 0.005 
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Asthma history 
 
1.  Distribution  
 
                       
                                     
 
Mild/moderate asthma 
(n= 145) 
 
 
Severe asthma 
(n=61) 
Age of diagnosis with breathing problems                    median (range) 12 ( 0 -50) 20 ( 0 – 58) 
Age of diagnosis with asthma 12 (0 – 50) 20 (0 – 58) 
Length of disease 15 (1 – 53) 18 (1-59) 
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2. Univariate analysis  
 
 Odds ratio (CI) Global p value 
Age of diagnosis with breathing 
problems 
1.029 ( 1.008 – 1.050) 0.006 
Age of diagnosis with asthma 1.025  (1.007  -  1.044) 0.007 
Length of disease 1.018  (0.995  -  1.042) 0.117 
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Asthma quality of life measurements 
 
1.  Distribution   
 
 
***AQL measurements are interpreted as lowest possible score = 1, highest possible score =  7**** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal 
N = 18 
 
Mild/moderate asthma 
N= 152 
 
Severe asthma 
N = 62 
Symptom score  
Median ( range)
 
7 ( 6.83 – 7) 
 
5.25 ( 1.083 – 7) 
 
4.29 ( 1 – 6.58) 
Activity score   
7 ( 6.81 – 7) 
 
5.09 ( 1 – 7) 
 
4.185 ( 1.545 – 6.545) 
Emotional score   
7 ( 7-7)` 
 
5.2 (1 – 7) 
 
4.4 ( 1 – 7) 
Environmental score   
7 ( 7 – 7) 
 
4.75 ( 1.25 – 7) 
 
4 ( 1 – 7) 
Overall AQL score  
7 ( 6.89 – 7) 
 
5.15 ( 1.125 – 6.938) 
 
4.17 ( 1.187 – 6.5) 
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   2. Univariate analysis  
 
 
 Odds ratio (CI) Global p-value 
Symptom score 1.494 (  1.185 - 1.884 ) 0.0005 
Activity score 1.691  (  1.310 - 2.181) < 0.0001 
Emotional score 1.251   ( 1.040 - 1.505) 0.017 
Environmental score 1.376 ( 1.119 - 1.692) 0.002 
Overall AQL score 1.598  ( 1.246 - 2.049) 0.0001 
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Asthma symptoms 
 
1. Distribution of symptom frequency
  
Mild/ moderate asthma 
N= 152 
 
Severe asthma 
N = 63 
Cough frequency 
Never
1x per month
Weekly but < 1x per day
2x per week but < 1x per day
Daily
At least 2x per day
 
23 ( 15.1) 
43 ( 28.3) 
29 ( 19.1) 
24 ( 15.8) 
19 ( 12.5) 
14 ( 9.2) 
 
4 ( 6.3) 
11 ( 17.5) 
13 ( 20.6) 
10 ( 15.9) 
9 ( 14.3) 
16 ( 25.4) 
Sputum frequency 
Never
1x per month
Weekly but < 1x per day
2x per week but < 1x per day
Daily
                                                At least 2x per day 
 
 
39 ( 25.7) 
41 ( 27.0) 
22 ( 14.5) 
23 ( 15.1) 
22 ( 14.5) 
5 ( 3.3) 
 
8 ( 12.7) 
12 ( 19.1) 
11 ( 17.5) 
7 ( 11.1) 
13 ( 20.6) 
12 ( 19.1) 
Chest tightness frequency 
Never
1x per month
Weekly but < 1x per day
2x per week but < 1x per day
Daily
                                                At least 2x per day 
 
 
26 ( 17.1) 
44 ( 29.0) 
28 ( 18.4) 
27 ( 17.8) 
21 ( 13.9) 
6 ( 4.0) 
 
4 ( 6.4) 
8 ( 12.7) 
24 ( 38.1) 
11 ( 17.5) 
13 ( 20.6) 
3 ( 4.8) 
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 1. Distribution of symptom frequency (continued)
  
Mild/ moderate asthma 
N= 152 
 
 
Severe asthma 
N = 63 
Wheeze frequency 
Never
1x per month
Weekly but < 1x per day
2x per week but < 1x per day
                              Daily
                                            At least 2x per day
 
19 ( 12.5) 
43 ( 28.3) 
39 ( 25.7) 
24 ( 15.8) 
22 ( 14.5) 
5 ( 3.3) 
 
5 ( 7.9) 
12 ( 19.1) 
21 ( 33.3) 
9 ( 14.3) 
10 ( 15.9) 
6 ( 9.5) 
Shortness of breath frequency 
Never
1x per month
Weekly but < 1x per day
2x per week but < 1x per day
                              Daily
                                            At least 2x per day
 
 
17 ( 11.2) 
38 ( 25.0) 
41 ( 27.0) 
27 ( 17.8) 
26 ( 17.1) 
3 ( 2.0) 
 
2 ( 3.2) 
7 ( 11.1) 
22 ( 34.9) 
9 ( 14.3) 
15 ( 23.8) 
8 ( 12.7) 
Nocturnal symptom frequency 
Never
1x per month
Weekly but < 1x per day
2x per week but < 1x per day
                              Daily
                                            At least 2x per day
 
 
58 ( 38.2)  
36 ( 23.7) 
16 ( 10.5) 
15 ( 9.9) 
22 ( 14.5) 
5 ( 3.3) 
 
15 ( 23.8) 
14 ( 22.2) 
8 ( 12.7) 
10 ( 15.9) 
12 ( 19.1) 
4 ( 6.4) 
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2. Distribution for overall measures of asthma symptoms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Mild/ moderate asthma 
N= 152 
 
Severe asthma 
 N = 63 
Duration of asthma attacks 
< 1 hour
1-6 hours
6-48 hours
> 2 days
 
93 ( 61.2) 
37 ( 24.3) 
15 ( 9.9) 
7 ( 4.6) 
 
29 ( 46.0) 
14 ( 22.2) 
11 ( 17.5) 
9 ( 14.3) 
Overall symptom frequency score 
                                 Median ( range) 
 
** Minimum possible score = 6 
     Maximum possible score = 36**** 
 
16.5 ( 6 – 36) 
 
20 ( 9-36) 
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3. Univariate analysis  
 
 Odds ratio (CI) Global p-value 
Cough frequency 1.373 ( 1.136 – 1.660) 0.0008 
Sputum frequency 1.142 ( 1.170 – 1.704) 0.0002 
Chest tightness frequency 1.314 ( 1.062 – 1.626) 0.011 
Wheeze frequency 1.223 ( 0.988 – 1.514) 0.064 
Shortness of breath frequency 1.494 ( 1.189 – 1.878) 0.0004 
Nocturnal symptom frequency 1.229 ( 1.026 – 1.472) 0.025 
Overall symptom frequency score 
 
1.091 ( 1.042 – 1.142) 0.0001 
Duration of asthma attacks 
 
1.560 ( 1.155 – 2.107) 0.004 
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Blood analysis 
 
1. Distribution of blood elements 
 
Element                
                 median (range) 
Reference values for adults 
(source: AHS) 
Mild/moderate asthma 
(n= 149) 
Severe asthma 
(n=63) 
WBC ct       
                                       
(x109/L) 
 
4.0 - 11.0  
 
6.55 ( 2.3 – 12.9) 
 
6.8 ( 3.9 – 13.5) 
Neutrophil ct 
(x109/L) 2.0 - 7.5  
 
3.8 ( 0.7 – 9.5) 
 
4.1 ( 1.8 – 11.9) 
Lymphocyte ct 
(x109/L) 1.0 - 4.0  
 
2.0 ( 1.0 – 4.5) 
 
1.8 ( 0.2 – 3.6) 
Monocyte ct 
(x109/L) 0.0 - 0.8  0.4 ( 0.1 – 1.1) 
 
0.4 ( 0 – 1) 
Eosinophil ct 
(x109/L) 0.0 - 0.5  0.2 ( 0 – 1.3) 
 
0.2 ( 0 – 1.3) 
Basophil ct 
(x109/L) 0.0 - 0.2  0 ( 0 - .2) 
 
0 ( 0 – 0.1) 
Neutrophil % 48 - 73  59 ( 29 – 82) 61 ( 34 – 95) 
 
Lymphocyte % 18 - 48  
 
30.7 ( 13 – 60) 27 ( 1.4 – 52) 
Monocyte % 0 - 9  
 
7 ( 1 – 14) 6 ( 0 – 11) 
Eosinophil % 0 - 5  3.35 ( 0 – 16) 3.1 ( 0 – 14) 
Basophil % 0 - 2  
 
0 ( 0 – 2) 0 ( 0 -1) 
Hb concentration 
male 
female 
 
130 - 180 g/L 
115 - 160 g/L 
13.8 ( 6.5 – 17) 
 
14.15 ( 9.7 – 16.4) 
IgE 
 For individuals > 15 years 
 
0-158 IU/ ml 158 ( 2 – 2822) 
 
119 ( 0 – 1325) 
Hematocrit 
male 
female 
 
0.38 - 0.52 
0.35 - 0.47 
0.41  ( 0.25 – 0.49 ) 
 
42 ( 31 – 48) 
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2. Univariate analysis 
 
 
 Odds ratio (CI) Global p value 
WBC ct         1.033 ( 0.885 – 1.205) 0.685 
Neutrophil ct 1.156 ( 0.964 – 1.387) 0.117 
Lymphocyte ct 0.635 ( 0.398 – 1.013) 0.048 
Monocyte ct 0.169 ( 0.026 – 1.111) 0.058 
Eosinophil ct 1.444 ( 0.382 – 5.461) 0.591 
Basophil ct 0.002 ( 0 – 1.481) 0.057 
Neutrophil % 1.029 ( 1.0 – 1.059) 0.047 
Lymphocyte % 0.972 ( 0.941 – 1.004) 0.079 
Monocyte % 0.850 ( 0.734 – 0.984) 0.026 
Eosinophil % 1.007 ( 0.909 – 1.115) 0.899 
Basophil % 0.552 ( 0.301 – 1.014) 0.048 
Hb concentration 1.115 ( 0.911 – 1.364) 0.282 
IgE 0.999 ( 0.998 – 1.000) 0.080 
Hematocrit 1.058 ( 0.979 – 1.143) 0.151 
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Family history 
 
1. Distribution 
 
  
Normal 
N = 18 
 
 
Mild/moderate asthma 
N= 152 
 
Severe asthma 
N = 63 
Father 
Asthma
Allergies
Eczema
 
1 ( 5.56) 
1 ( 5.56) 
0 
 
31 ( 21.38) 
45 ( 32.37) 
14 ( 9.66) 
 
5 ( 8.20) 
17 ( 28.81) 
1 ( 1.64) 
Mother 
Asthma
Allergies
Eczema
 
2 ( 11.11) 
3 ( 16.67) 
1 ( 5.56) 
 
36 ( 24.83) 
61 ( 42.96) 
9 ( 6.04) 
 
11 ( 18.03) 
29 ( 48.33) 
3 ( 4.92) 
Siblings 
Asthma
Allergies
Eczema
 
2 ( 11.11) 
3 ( 16.67) 
2 ( 11.11) 
 
49 ( 38.89) 
61 ( 50.00) 
17 ( 12.98) 
 
21 ( 37.50) 
30 ( 57.69) 
7 ( 12.50) 
Child (ren) 
Asthma
Allergies
Eczema
 
0 
2 ( 18.18) 
2 ( 18.18) 
 
22 ( 2821) 
41 ( 50.62) 
8 ( 9.52) 
 
 
13 ( 30.95) 
24 ( 54.55) 
7 ( 15.91) 
# of siblings  
                                         Median ( range)
 
2 ( 0 -8) 
 
2 ( 0 – 7) 
 
2 ( 1 – 9) 
# of children 
Median ( range)
 
 0 ( 0– 2) 
 
0 ( 0 – 4) 
 
0 ( 0 – 5) 
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2. Univariate analysis 
 
 Odds ratio (CI) Global p-value 
Father 
Asthma
Allergies
Eczema
 
 
0.328 ( 0.121 – 0.890) 
0.845 ( 0.434 – 1.646) 
0.156 ( 0.020 – 1.213) 
 
0.016 
0.620 
0.022 
 
Mother 
Asthma
Allergies
Eczema
 
0.666 ( 0.313 – 1.415) 
1.242 ( 0.678 – 2.276) 
0.805 ( 0.210 – 3.079) 
 
0.281 
0.483 
0.747 
 
Siblings 
Asthma
Allergies
Eczema
 
0.943 ( 0.493 – 1.804) 
1.364 ( 0.708 – 2.624) 
0.958 ( 0.974 – 2.457) 
 
0.859 
0.352 
0.929 
 
Child (ren) 
Asthma
Allergies
Eczema
 
1.141 ( 0.503 – 2.589) 
1.171 ( 0.561 – 2.444) 
1.798 ( 0.606 – 5.334) 
 
0.753 
0.674 
0.295 
 
# of siblings                                          1.199 ( 1.019 – 1.408) 0.028 
# of children 1.672 ( 1.295 – 2.159) < 0.0001 
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For women only 
 
1. Distribution 
 
  
Normal 
N = 11 
 
Mild/moderate asthma 
N = 106 
 
Severe asthma 
N = 39 
Respiratory symptoms during and 
around monthly menses 
 
0 
 
 
14 ( 13.21) 
 
6 ( 15.79) 
Hormone replacement therapy  
0 
 
2 ( 1.83) 
 
8 ( 20.51) 
Surgery uterus  
0 
 
10 ( 9.17) 
 
8 ( 20.51) 
Surgery ovaries  
0 
 
8 ( 7.34) 
 
8 ( 20.51) 
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2. Univariate analysis 
 
 Odds ratio (CI) Global p-value 
Respiratory symptoms about or 
during monthly menses 
 
1.232 ( 0.437 – 3.477) 
 
0.696 
Hormone replacement therapy  
13.806 ( 2.787 – 68.399) 
 
0.002 
Surgery uterus  
2.555 ( 0.927 – 7.039) 
 
0.076 
Surgery ovaries  
3.258 ( 1.130 – 9.398) 
 
0.032 
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Lung function test ( Spirometry) 
 
1. Distribution 
 
  
Normal 
N = 18 
 
 
Mild/moderate asthma 
N = 151 
 
Severe asthma 
N = 63 
FEV1 baseline                median (range) 3.82 ( 2.77 – 4.9) 2.66 ( 0.88 – 6.22) 2 ( 0.68 – 4.51) 
Pre-bronchodilator FEV1 predicted 3.81 ( 2.56 ( 4.94) 3.16 ( 2.15 – 5.33) 3.24 ( 1.99 – 5.01) 
FEV1  percent predicted 100.5 ( 83 – 123) 84 ( 27 – 121) 68 ( 24 – 110) 
FVC baseline 4.46 ( 3.28 – 6.25) 3.59 ( 1.58 – 7.93) 3.15 ( 0.95 – 5.78) 
Pre-bronchodilator FVC predicted 4.15 ( 3.16 – 5.98) 3.79 ( 2.59 – 6.57) 3.98 ( 2.62 – 6.31) 
Pre-bronchodilator FEF 3.93 ( 2.59 – 6.07) 2.17 ( 0.40 – 5.32) 1.13 ( 0.22 – 4.18) 
Pre-bronchodilator FEF predicted 3.82 ( 2.63 – 5.07) 3.5 ( 2.11 – 5.27) 3.19 ( 1.47 – 4.65) 
Pre-bronchodilator PEF 8.27 ( 5.69 – 11.31) 6.75 ( 1.43 – 14.57) 5.62 ( 2.04 – 10.68) 
Pre-bronchodilator PEF predicted 7.35 ( 5.44 – 11.05) 7.09 ( 2.61 – 11.65) 7.41 ( 5.27 – 11.5) 
Post-bronchodilator FEV1 3.86 ( 3.01 – 4.94) 2.84 ( 1.37 – 6.3) 2.27 ( 0.7 – 4.36) 
Post-bronchodilator FEV1 predicted 104 ( 86 – 125) 92 ( 42 – 124) 73 ( 24 – 119) 
Post-bronchodilator FVC 4.51 ( 3.44 – 6.3) 3.68 ( 1.67 – 8.11) 3.32 ( 0.93 – 5.33) 
Percent difference FEV1 3.2 ( 0 – 54) 7.15 ( -1.6 – 68.2) 8.6 ( -3.3 – 91.1) 
Post-bronchodilator FEF 4.14 ( 2.59 – 5.95) 2.75 ( 0.64 – 6.34) 1.39 ( 0.26 – 5.67) 
Post-bronchodilator PEF 8.08 ( 4.8 – 11.27) 7.28 ( 3.23 – 14.7) 6.21 ( 2.36 – 11.22) 
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2. Univariate analysis 
 
 Odds ratio ( CI) Global p-value 
FEV1 baseline 0.359 ( 0.236 – 0.547) < 0.0001 
FEV1  percent predicted 0.951 ( 0.934 – 0.968) < 0.0001 
FVC baseline 0.578 ( 0.423 – 0.789) 0.0002 
Pre-bronchodilator FEF 0.393 ( 0.269 – 0.574) < 0.0001 
Pre-bronchodilator PEF 0.702 ( 0.589 – 0.837) < 0.0001 
Post-bronchodilator FEV1 0.341 ( 0.221 – 0.525) < 0.0001 
Percent difference FEV1 1.015 ( 0.993 – 1.037) 0.185 
Post-bronchodilator FVC  0.654 ( 0.484 – 0.884) 0.004 
Post-bronchodilator FEF 0.418 ( 0.301 – 0.581) < 0.0001 
Post-bronchodilator PEF 0.730 ( 0.612 – 0.871) 0.0002 
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Medical care utilization 
 
1.  Distribution 
 
  
Mild/moderate asthma 
N = 152 
 
 
Severe asthma 
N = 63 
One or more urgent care visits in the last 12 months  
37 ( 22.16) 
37 ( 44.05) 
Frequency of these visits 
No more than 2x per year
At least 2x per year but no more than 4
More than 4x but less than 1x per month
More than 1x per month
 
23 ( 62.16) 
10 ( 27.03)  
4 ( 10.81) 
0 
 
9 ( 25.71) 
16 ( 45.71) 
9 ( 25.71) 
1 ( 2.86) 
Seen a doctor in the last 12 months due to breathing problems  
73 ( 48.03) 
 
55 ( 87.30) 
ER ever for breathing problems  
90 ( 59.60) 
 
48 ( 76.19) 
ER last 12 months for breathing problems  
21 ( 20.00) 
 
16 ( 30.19) 
Hospitalization ever for breathing problems  
45 ( 30.00) 
 
39 ( 61.90) 
Hospitalization last 12 months for breathing problems  
3 ( 4.29) 
 
9 ( 19.57) 
ICU ever for breathing problems  
10 ( 6.62) 
 
17 ( 27.42) 
ICU for asthma  
7 ( 77.78) 
 
5 ( 38.46) 
Intubation due to asthma attack  
3 ( 75.00) 
 
4 ( 44.44) 
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2. Univariate analysis 
 
 Odds ratio ( CI) Global p-value 
One or more urgent care visits in the last 12 months 2.766 ( 1.572 – 4.865) 0.0004 
Frequency of these visits 
No more than 2x per year
At least 2x per year but no more than 4
More than 4x but less than 1x per month
More than 1x per month
 
Base category 
4.089 ( 1.356 – 12.329) 
5.75 ( 1.407 – 23.492) 
n/a 
For model: 0.008 
 
0.012 
0.015 
Seen a doctor in the last 12 months due to breathing problems 7.440 ( 3.320 – 16.675) < 0.0001 
ER ever for breathing problems 2.169 ( 1.116 – 4.216) 0.018 
ER last 12 months for breathing problems 1.730 ( 0.812 – 3.686) 0.159 
Hospitalization ever for breathing problems 3.792 ( 2.046 – 7.026) < 0.0001 
Hospitalization last 12 months for breathing problems 5.432 ( 1.385 – 21.313) 0.008 
ICU ever for breathing problems 5.327 ( 2.276 – 12.464) 0.0001 
ICU for asthma 0.178 ( 0.026 – 1.228) 0.063 
Intubation due to asthma attack 0.267 ( 0.019 – 3.653) 0.298 
 
  158
Medication use (asthma-specific) 
 
1. Distribution 
 
  
Mild/moderate asthma 
N = 167 
 
 
Severe asthma 
N = 83 
Frequency of rescue inhaler use 
 
Never
1x per month
Weekly but < 2x per week
More than 2x per week
 
 
 
42 ( 27.63) 
59 ( 38.82) 
28 ( 18.42) 
23 ( 15.13) 
 
 
8 ( 12.70) 
21 ( 33.33) 
16 ( 25.40) 
18 ( 28.57) 
Use of oral corticsteriods 1 ( 0.60) 18 ( 21.43) 
Use of inhaled corticosteroids 6 ( 3.59) 80 ( 96.39) 
Daily use of β-agonist inhaler 52 ( 31.14) 77 ( 91.67) 
Additional 76 ( 45.51) 57 ( 67.86) 
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2. Results of univariate analysis. 
 
 Odds ratio ( CI) Global p-value 
Frequency of rescue inhaler use 
 
Never
1x per month
Weekly but < 2x per week
More than 2x per week
 
 
 
------ 
1.869 ( 0.756 – 4.651) 
3.00 ( 1.132 – 7.946) 
4.109 ( 1.549 – 10.901) 
 
 
------ 
0.176 
0.027 
0.005 
Use of oral corticsteriods 45.273 ( 5.924 – 345.95) < 0.0001 
Use of inhaled corticosteroids 715.555 ( 174.420 – 2935.569) < 0.0001 
Daily use of β-agonist inhaler 4.669 ( 2.659 – 8.198) < 0.0001 
Use of additional controller medication 13.171 ( 5.735 – 30.251) < 0.0001 
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Pet ownership 
 
1. Distribution 
 
  
Normal 
N = 18 
 
Mild/moderate asthma 
N = 152 
 
Severe asthma 
N = 63 
Own cat  
9 ( 50) 
 
38 ( 25.00) 
 
15 ( 23.81) 
Own dog  
2 ( 11.11) 
 
42 ( 27.63) 
 
22 ( 34.92) 
Own birds  
1 ( 5.56) 
 
4 ( 2.63) 
 
2 ( 3.17) 
 
Own rodents  
1 ( 5.56) 
 
0 
 
1  (1.59) 
Own other pets  
2 ( 11.11) 
 
21 ( 13.82) 
 
5 ( 7.94) 
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2. Univariate analysis. 
 
 Odds ratio ( CI) Global p-value 
Own cat  
0.938 ( 0.472 – 1.862) 
 
0.853 
Own dog  
1.405 ( 0.750 – 2.634) 
 
0.291 
Own birds  
1.213 ( 0.216 – 6.798) 
 
0.828 
Own rodents  
----------------- 
 
------------- 
Own other pets  
0.538 ( 0.193 – 1.496) 
 
0.212 
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Provoking factors  
 
1. Distribution 
 
  
Mild/moderate asthma 
N = 152 
 
Severe asthma 
N = 63 
Recent exposure causing asthma 
symptoms to worsen 
 
14 ( 9.27 ) 
 
8 ( 12.70) 
Asthma provoked by an animal  
100 ( 66.67) 
 
35 ( 55.56) 
Asthma provoked by a routine 
physical activity 
 
74 ( 48.68) 
 
47  ( 75.81) 
Asthma provoked by exercise  
117 ( 77.48) 
 
53 ( 91.38) 
Asthma provoked by aspirin  
12 ( 8.22) 
 
8 ( 13.79) 
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2.  Univariate analysis 
 
 Odds ratio ( CI) Global p-value 
Recent exposure causing asthma 
symptoms to worsen 
1.423 ( 0.565 – 3.583) 0.460 
Asthma provoked by an animal 0.625 ( 0.342 – 1.141) 0.127 
Asthma provoked by a routine 
physical  activity 
3.303 ( 1.703 – 6.406) 0.0002 
Asthma provoked by exercise 3.080 ( 1.141 – 8.317) 0.014 
Asthma provoked by aspirin 1.787 ( 0.690 – 4.628) 0.241 
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Respiratory and non-respiratory co-morbidities 
 
1. Distribution 
 
  
Normal 
N = 18 
 
 
Mild/ moderate asthma 
N = 152 
 
Severe asthma 
N = 63 
Pneumonia 2 ( 11.11) 53 ( 35.81) 39 ( 61.90) 
Bronchitis w/ antibiotic treatment 2. ( 12.50) 59 ( 39.86) 33 ( 52.38) 
Chronic bronchitis 0 12 ( 8.05) 6 ( 9.52) 
Sinusitis w/ antibiotic treatment 0 59 ( 38.82) 40 ( 63.49) 
Sinus surgery  0 17 ( 11.18) 19 ( 30.16) 
Nasal polyps 0 9 ( 6.12) 14 ( 22.22) 
Nasal polyp surgery 0 7 ( 4.64) 14 ( 22.22) 
Gastroesophageal reflux disease 
(GERD) 
0 25 ( 16.78) 28 ( 44.44) 
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2. Univariate analysis. 
 
 Odds Ratio ( CI) Global p-value 
Pneumonia 2.913 ( 1.583 – 5.358) 0.0005 
Bronchitis w/ antibiotic treatment 1.659 ( 0.916 – 3.005) 0.094 
Chronic bronchitis 1.202 ( 0.430 – 3.358) 0.728 
Sinusitis w/ antibiotic treatment 2.741 ( 1.493 – 5.034) 0.0009 
Sinus surgery  3.429 ( 1.640 – 7.169) 0.001 
Nasal polyps 4.381 ( 1.784 – 10.760) 0.001 
Nasal polyp surgery 5.878 ( 2.243 – 15.403) 0.0002 
Gastroesophageal reflux disease 
(GERD) 
3.968 ( 2.057 – 7.654) < 0.0001 
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Tobacco use and exposure 
 
1. Distribution 
 
  
Normal 
N = 18 
 
Mild/moderate asthma 
N = 152 
 
Severe asthma 
N = 63 
Current smoker 1 ( 5.56) 23 ( 15.13) 9 ( 14.29) 
Age onset smoking 38 ( 38 – 38) 16 ( 10 – 21) 19 ( 16 – 23) 
Exposure to 2nd hand smoke 2 ( 11.11) 40 ( 26.32) 15 ( 23.81) 
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2. Univariate analysis.  
 
   
 Odds ratio ( CI) Global p-value 
Current smoker 0.935 ( 0.406 – 2.151) 0.874 
Age onset smoking 1.617 ( 1.058 – 2.473) 0.008 
Exposure to 2nd hand smoke 0.875 ( 0.442 – 1.732) 0.700 
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APPENDIX B  
Supplemental Methods from Chapter 3 
 
 
Study cohort 
 
In September 2001, the Severe Asthma Research Project (SARP),  a collaborative, multi-city 
study was commenced to obtain a more comprehensive understanding of severe asthma. One 
objective of the study was to investigate the prevalence of suspect risk factors for disease 
severity in adult asthmatics.  Individuals recruited for the study were between the ages of 19-59 
years.   Each city worked under a standardized definition of severe asthma (as defined by the 
SARP steering committee) and uniform inclusion criteria for severe asthma.  Patients who 
reported having been diagnosed with asthma were assessed for asthma severity based on the 
following criteria: 
Major criteria (individual must satisfy at least one of the following): 
• Treatment with continuous or near-continuous oral corticosteroids 
• Treatment with continuous high-dose inhaled corticosteroids 
 
Minor Criteria: (individual must satisfy at least two of the following) 
 
• Require daily treatment with controller medication in addition to inhaled 
• Asthma symptoms require short-acting β-agonist use on a daily or near daily basis 
• Persistent airway obstruction, as determined by FEV1 < 80% predicted and diurnal PEF 
variability > 20% 
• One or more urgent care visits for asthma per year 
• Three or more oral corticosteroid bursts per year 
• Prompt deterioration with reduction in oral or inhaled corticosteroid dose 
• Near-fatal asthma event in the past 
 
Asthmatic subjects who did not satisfy the above criteria for severe asthma were classified as not 
severe. The point-prevalence nature of this study did not accommodate for matching of subjects.   
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Data 
 
General.  All qualified subjects, upon enrollment into the SARP, were asked to sign a consent 
form which permits the sharing of their data and/or biological samples across the SARP study 
sites.   Original samples and data collected from study subjects remained at the site of collection 
and were shared with other SARP sites upon approval by the SARP steering committee.  
 
Screening.  Prospective study subjects are screened for eligibility based on their smoking history, 
respiratory disease other than asthma (ie CF and VCD), diagnosis with asthma, length of disease, 
asthma medication and attack history, and satisfaction of the aforementioned major and minor 
criteria for severe asthma.  
 
Questionnaire.  Upon qualification for study enrollment, patient was asked to complete 
additional sections of the SARP questionnaire.  These sections included: 
• Asthma Quality of Life 
• Atopy history 
• Demographic information 
• Environmental factors specific to pet ownership 
• Family allergy and asthma history 
• General symptoms of respiratory disease 
• Medical history, including co-morbidities and health care utilization 
• Medication history 
• Provoking factor exposure specific to asthma symptoms 
• Smoking and ETS exposure history 
• Symptoms and exposures exclusive to women (i.e. reproductive, hormones). 
 
 
Blood work. Blood was drawn from all study subjects either at screening for study eligibility or 
at a subsequent visit.  Each Clinical Center is responsible for drawing blood from SARP subjects 
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in order to obtain blood counts and differentials, IgE, hematocrit, and hemoglobin.  Labels for 
each subject's blood and serum tubes are uniformly labeled with the study subject’s SARP ID# 
and blood draw date.  The labeling is coordinated Dr. Doug Everett, SARP Data Collection 
Coordinator at the National Jewish Medical Center, Denver, CO.  Site laboratories determine the 
blood counts and differentials, serum IgE, hematocrit, and hemoglobin.  The results were entered 
on the SARP Blood Draw Form.   
 
Allergy skin test. Skin testing will be done all adult SARP study subjects. Study subjects were 
screened for medication use, including certain over-the-counter medicines, taken within the 
preceeding 24 hours of testing.  Percutaneous (puncture) skin testing was performed on the 
subject's  forearm with at least 2-cm spacing between tests.  The Multi-Test II device (Lincoln 
Diagnostics, Decatur, Illinois) was used to provide allergen to the study subject’s forearm The 
Multi-Test II meets OSHA guidelines for technician protection, and has been reported to provide 
a lower coefficient of variation than similar devices.  The allergens included in the skin test were 
as follows: 
• Dermatophagoides pteronyssinus 
• Dermatophagoides farinae 
• Cat 
• Dog 
• American cockroach 
• Alternaria 
• Cladosporium 
• Aspergillus mix 
• Timothy grass (or grass mix) 
• Short ragweed 
• Common weed mix: cocklebur, lambs quarter, pigweed, English plantain, Russian thistle 
• Eastern 7-tree mix: white ash, American beech, red birch, American elm, shagbark 
hickory, red oak, cottonwood 
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The core extracts were ordered by each Clinical Center from Greer Laboratories, Lenoir, NC. 
Negative controls consisted of 50% glycerin in 50% saline and positive controls consist of 1 
mg/ml histamine base.  Significant skin tests are those in which the application of an allergen 
produces a wheal with the largest diameter of 3 mm or more than the negative control AND a 
flare with the largest diameter of 10 mm or more. Values were then recorded on the SARP skin 
testing form. 
In the event of a systemic-allergic reaction (anaphylaxis), injectable epinephrine (1:1000) was 
present for injection.    
 
Lung function test. Spirometry is the timed-based measurement of the amount of air which can 
be forcefully exhaled from the lungs after a full inspiration. The SARP is concerned primarily 
with 4 measurements during spirometry:  
• Peak flow (PEFR)- the maximum flow that occurs during the procedure  
• Forced expiratory volume in 1 second (FEV1)- the volume of air that is blown out during 
peak flow is the 1st second of the procedure and 
• Forced vital capacity (FVC)- the total amount of air that leaves the lung during the 
proceedure  
• FEV1=FVC ratio-an additional useful calculation which is the fraction or percent of the 
total volume of air expired that can be exhaled in one second.  
 
The SARP uses these measures to determine the severity of asthma in the study subjects.  
Prior to spirometry, subjects are screened for intake of certain drugs and substances within 48 
hours of the lung function test. If asthma medication was withheld during lung function test, 
a post-bronchodilator test is administered and the 4 aforementioned measurements are re-
collected.  
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Serological analysis for respiratory pathogens.  Serum from study subjects was obtained for 
serological analysis.  Of interest was the sero-prevalence of  antibodies indicative of respiratory 
infection cause by Mycoplasma pneumoniae (Mpn) and Chlamydia pneumoniae (Cpn).  An 
Enzyme-Linked Immunosorbent Assay (ELISA) specific for the detection of Mpn- and Cpn-
specific IgM, IgG, and IgA was used (Savyon Diagnostics, Ashdod, Israel).  The serological 
analysis was performed at University of Wisconsin under the direction of William H. Busse, 
M.D., SARP steering committee chair.        
To test for infection with Mpn, the unit of measurement was an arbitrary binding unit (BU)/ ml 
of sample.  Determinations of infection were as follows: 
• < 10BU/ ml = negative (no indication of Mpn infection) 
• 10 and < 20 BU/ ml = borderline (Indicative of exposure but not of infection. A 
secondary analysis of an additional second serum sample  taken 2-3 weeks later should be 
conducted; second borderline result should be interpreted as negative) 
• 20 BU/ml = positive (indication of infection by Mpn) 
To test for infection with Cpn, the unit of measurement was the absorbance (OD) of the sample.  
The reference value was the cut-off value (COV) that is calculated as follows:0 
                                            COV = NC x 2   (NC = the average absorbance at 450 nm  
                                                                            of the Negative Control run in duplicate). 
 
Determinations of infections were as follows:  
 
• O.D. < COV = Negative (no indication of infection by Cpn) 
• COV < O.D.  < 1.1 x COV = Borderline (indicative of exposure but not of infection. 
Secondary analysis of an additional serum sample taken 2-3 weeks later should be 
conducted; second borderline result should be interpreted as negative) 
• O.D. > 1.1 x COV = Positive (indication of infection by Cpn).  
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Using the aforementioned determinations of infections, serum was analyzed for the prevalence of 
IgM (current infection), IgG (past infection) and IgA (chronic infection).  The presence of IgA 
antibodies is also an indicator of chronic mucosal stimulation.  
 
 
Data analysis 
Coding and format of variables.  The outcome of interest is the phenotype of “severe” asthma.   
Although the hypothesis of this study tests whether the prevalence of atypical pathogens 
contributes to asthma severity is adults, data collected from the questionnaires and clinical tests 
is also tested for their relationship to severe asthma.  Most of the data from the questionnaire and 
all of the data from the skin test are formatted as binary responses (0=no, 1=yes).  Data from the 
serological analysis was sorted into 2 sets: data coded as binary responses (ie – or + for 
infection) and data coded as categorical responses (ie. current, past or chronic infection).  These 
2 sets of responses were analyzed separately for their relationship to severe asthma.  Data from 
the blood work and lung function test retained their original continuous format.      
 
The 5 confounding variables to be controlled for. Based on the recent literature regarding risk 
factors for adult asthma severity, current age and female gender were selected as variables that 
will be controlled for.  Since recent evidence suggests that a person’s body mass index (BMI) 
may contribute to poor health outcomes in those with chronic disease, BMI was also controlled 
for. Finally, since the influence of age of asthma onset and years with asthma on disease severity 
is poorly understood, these variables were also selected for controlling.  
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Logistic regression. The goal of logistic regression is to find the best fitting (yet biologically 
reasonable) model to describe the relationship between the dichotomous characteristic of interest 
(dependent variable = response or outcome variable) and a set of independent (predictor or 
explanatory) variables Logistic regression generates the coefficients (and its standard errors and 
significance levels) of a formula to predict a logit transformation of the probability of presence 
of the characteristic of interest: 
 
where p is the probability of presence of the characteristic of interest. The logit transformation is 
defined as the logged odds: 
 
and 
 
 
Univariate analysis.  The outcome of interest is binary: 0= mild/moderate asthma and 1=severe 
asthma. Using logistic regression, all variables are assessed individually for their relationship to 
severe asthma.  Those with a p-value <  0.20 are extracted and retained for further analysis.  
 
Stepwise “backward” regression analysis and severe asthma model.  The goal of logistic 
regression is to correctly predict the category of outcome (ie asthma severity) for individual 
cases.  Stepwise regression is a form of logistic regression that tests the fit of the model after 
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individual variables are added or deleted and is used to explore the relationship of predictor 
variables to the outcome of interest.  Backward stepwise regression is the analysis that begins 
with a full or saturated model and variables are deleted from the model in an iterative process. 
The fit of the model is tested after the elimination of each variable to ensure that the model still 
adequately fits the data. When no further variables can be eliminated from the model, the 
analysis has been completed.   However in all cases, the p value criteria for entry into the model 
must be less than removal.  Standard practice in epidemiology and biostatistics is p= 0.15 for 
entry of a predictor variable into the stepwise elimination model and p= 0.20 for removal.    
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